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ABSTRACT
The size and complexity of eukaryotic genomes require that specific mechanisms exist
for ensuring both the stability as well as the accessibility of DNA. One such mechanism
is the association of DNA with histones to form chromatin, the physiological substrate of
gene expression. An important means by which histones impact transcriptional activity is
through site-specific enzymatic modification of the amino terminal histone “tails”, which
can alter the spectrum of chromatin-associated proteins and hence transcriptional states.
Among the known modifications of histones, lysine methylation has been proposed to
represent a relatively stable mark which might mediate stable activation or repression,
depending upon the site modified.
The immune system provides an ideal system in which to test the physiological
functions of particular chromatin-modifying activities, since proper lymphocyte
development and function requires integration of multiple signals, both cell autonomous
and receptor-mediated, with complex DNA recombination reactions which are unique to
lymphocytes. We have exploited these features to explore the possible functions of
histone 3, lysine 3 (H3K9) methylation in the immune system through conditional
inactivation of the H3K9-specific methyltransferases G9a and GLP.
These studies demonstrate that G9a is essential for B cell development in the mouse,
but is dispensable for T cell development. The defect in B lymphopoiesis in the absence
of G9a is caused by a block in development at the pro-B cell stage, corresponding to the
onset of immunoglobulin heavy chain recombination. The overall normal behavior of
G9a-deficient peripheral B cells argues in favor of the specificity of this effect.

Furthermore, through analysis of G9a and GLP protein sequences, we have identified
a novel mechanism by which chromatin-modifying complexes can be regulated. We find
that both G9a and GLP contain conserved H3K9-like motifs, on which the main
biochemical features of H3K9 itself are recapitulated. Considering both the sequence and
functional conservation between these sites and histones, we term these motifs in nonhistone proteins “histone mimics”. Our initial analysis indicates that many chromatinassociated proteins potentially contain H3K9-type histone mimics, and that this
phenomenon is therefore likely to be a general one.

If you seek Truth, you will not seek to gain a victory by every possible means;
and when you have found Truth, you need not fear being defeated.
Epictetus
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CHAPTER 1: INTRODUCTION
1.1 Histone modifications and gene expression
A fundamental problem facing all organisms is the question of how to package, access
and transmit genetic information. These three aims would appear to be mutually
exclusive, since packaging and transmission of the genome clearly require compaction of
DNA, whereas accessing DNA to allow transcription requires decondensation. All three
of these problems are addressed in eukaryotes through the association of DNA with
histones. Histones are small, highly basic proteins which interact directly and sequence
non-specifically with DNA, forming the nucleoprotein complex known as chromatin.
Packaging of DNA into chromatin allows compaction of up to 10,000-fold, allowing
stable storage as well as propagation of the genome through mitosis.
The fundamental repeating unit of chromatin is the nucleosome core particle,
consisting of 147 bp of DNA wrapped in 1.75 turns around a core histone octamer. This
octamer consists of a histone 3/histone 4 (H3/H4) tetramer (itself made of two H3/H4
dimers) and two H2A/H2B dimers (Khorasanizadeh, 2004; Luger et al., 1997). The
compaction of DNA caused by its packaging into chromatin can be increased by the
further association with the linker histone, H1. Incorporation of H1 stabilizes a more
condensed packing of nucleosomes in vitro, and promotes compaction into a 30 nm
diameter fiber (Hayes and Hansen, 2001).
Histones were originally thought to be relatively inert “scaffolding” molecules, which
themselves played little part in the regulation of gene expression. This view has given
ground, though, with recent rapid advances made in understanding the many active
processes which manipulate histones. These include ATP-dependent chromatin
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remodeling (Lusser and Kadonaga, 2003), histone replacement with variants having
distinct functional properties (Ahmad and Henikoff, 2002), and direct post-translational
modification of core histones (Strahl and Allis, 2000). The study of histone modification
in particular has seen explosive growth as it has become clear that a vast array of
modifications can and do occur on all of the core histones. These modifications include
serine and threonine phosphorylation (Nowak and Corces, 2004), lysine acetylation
(Kouzarides, 2000; Mizzen and Allis, 1998; Roth et al., 2001), lysine and arginine
methylation (Kouzarides, 2002; Lachner and Jenuwein, 2002), lysine ubiquitination
(Briggs et al., 2002; Sun and Allis, 2002), as well as other less studied modifications (e.g.
sumoylation, ADP-ribosylation, glycosylation and biotinylation). A list of the most wellstudied modifications and the enzymes carry them out is given in Figure 1.1.

Figure 1.1 Partial description of histone modifications and modifying enzymes.
Reproduced from Margueron et al., 2005.

2

Histone modifications can be broadly divided into those associated with active
transcription (euchromatin-associated), and those associated with transcriptional
repression (heterochromatin-associated). A subset of these are shown schematically in
Figure 1.2. One prominent mark seen on active loci is histone phosphorylation,
especially on H3 serine 10 (H3S10), which is associated both with chromosome
condensation during mitosis as well as transcriptional activation (Nowak and Corces,
2000; Wei et al., 1999). Histone acetylation is also strongly correlated with
transcriptional activity, and is perhaps the most well-studied mark of transcriptional
activation (Allfrey et al., 1964; Kouzarides, 2000; Kuo et al., 1996). While it is still not
completely clear how or indeed whether these modifications directly promote
transcription, the existing evidence strongly indicates a causal relationship (Anest et al.,
2003; Brownell et al., 1996; Chan and La Thangue, 2001; Yamamoto et al., 2003).

Figure 1.2 Histone modifications associated with euchromatin and
heterochromatin. Abbreviations: Ac, acetylation; Me, methylation; P,
phosphorylation. Adapted from Jenuwein and Allis (2001)
3

In contrast to phosphorylation and acetylation, the effects of histone lysine
methylation on transcriptional activity seem to depend critically on the site of
modification. Thus, while methylation of lysine 4 in the amino-terminal “tail” of histone
3 (H3K4) correlates with activation of transcription (Santos-Rosa et al., 2002),
methylation of lysines 9 or 27 of the H3 tail (H3K9 and H3K27) is strongly correlated
with transcriptional repression (Cao et al., 2002; Rea et al., 2000; Snowden et al., 2002).
Lysine methylation is further complicated by the possibility of mutually exclusive
modification on the same residue (e.g. acetylation versus methylation of H3K9), as well
as by antagonism of modifications on different residues. One example of this antagonism
is the described inhibition of H3K9 methylation by preexisting H3S10 phosphorylation
(Rea et al., 2000). Furthermore, differences in modification density (e.g. mono-, di- and
tri-methylation) can significantly effect the distribution of these marks: while H3K4
trimethylation in yeast is found mainly at the 5’ end of actively transcribed genes,
dimethylation in generally located in the middle of the open reading frame, and
monomethylation at the 3’ end (Pokholok et al., 2005).

1.2 Writing and reading histone modifications
To date, all except one of the known histone methyltransferases (HMTases) contains
the evolutionarily conserved SET domain (Dillon et al., 2005). The SET domain was
named for the three founding members of the family, SuVar(3-9), Enhancer of Zeste
[E(z)], and Trithorax. All three of these proteins were known from their respective
mutant phenotypes in Drosophila to be involved in epigenetic regulation (AlvarezVenegas and Avramova, 2002; Schotta et al., 2002; Schumacher and Magnuson, 1997).
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It has since become clear that these proteins all have intrinsic SET domain-dependent
HMTase activity: SuVar(3-9), E(z) and Trithorax (as well as their mammalian homologs,
Suv39H1/2, Ezh1/2 and MLL), catalyze H3K9, H3K27 and H3K4 methylation
respectively.
For the most part, multiple HMTases seem to contribute to methylation of any given
site in histones (Figure 1.1). However, knockout studies in mice have demonstrated that
a subset of these HMTases are necessary for the vast majority of the methylation mark
which they place. For instance, disruption of the murine E(z) homolog Ezh2 or its
obligate binding partner Eed leads to a dramatic decrease in total H3K27 trimethylation,
demonstrating that little redundancy exists for methylation of this site (Montgomery et
al., 2005; Su et al., 2003; Su et al., 2005). Similarly, double mutation of Suv39H1/2
leads to complete loss of heterochromatic H3K9 trimethylation (Peters et al., 2001; Rea
et al., 2000). Remarkably, although triMeH3K9 is lost, H3K9 dimethylation
(diMeH3K9), a transcriptionally repressive mark normally present in euchromatic
chromosomal territories, is unaffected (Peters et al., 2003; Rice et al., 2003). This is
logical, as placement of the diMeH3K9 mark is catalyzed not by Suv39H1/2, but by the
HMTases G9a and G9a-like protein (GLP, also known as EuHMTase-1). Loss of either
G9a or GLP severely decreases euchromatic diMeH3K9, while leaving triMeH3K9 levels
unchanged (Peters et al., 2003; Rice et al., 2003; Tachibana et al., 2002; Tachibana et al.,
2005).
A major breakthrough in our understanding of the physiological functions of these
varying histone modifications came with the discovery that particular modifications
produce binding sites for “effector modules”, which recognize modified residues with
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high specificity. This is true, for instance, of acetyllysine, which is recognized and bound
by proteins containing the bromodomain (Dhalluin et al., 1999; Jacobson et al., 2000;
Owen et al., 2000), which is found in nearly all histone acetyltransferases (HATs).
Similarly, methyllysine can be specifically recognized by the chromodomain (Bannister
et al., 2001; Jacobs et al., 2001; Lachner et al., 2001), and has more recently been shown
to interact with Tudor domains as well (Huyen et al., 2004).

Figure 1.3 Summary of methylated histone binding proteins. Histones shown
in red, DNA in blue. Abbreviations: CHD1, chromodomain helicase DNA-binding
protein 1; HP1, heterochromatin protein 1; PC, Polycomb protein; p53BP1, p53binding protein 1; CRB2, Cut5-repeat-binding protein 2. Adapted from Bannister
and Kouzarides (2005).

Methylation of lysine 9 in H3 (H3K9) is recognized by chromodomain-containing
proteins of the Heterochromatin Protein 1 (HP1) family, whereas methylation of H3K27
is recognized by chromodomain-containing Polycomb group proteins (Fischle et al.,
2003b). In at least one protein, the Arabidopsis chromodomain-containing DNA
methyltransferase CMT3, recognition of methylated H3 seems to require simultaneous
methylation of both K9 and K27 (Lindroth et al., 2004). In addition, a recent report
demonstrated that the chromodomain helicase CHD1 specifically binds methylated H3K4
(Pray-Grant et al., 2005). These interactions are summarized in Figure 1.3. Binding of
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effector modules to methylated lysine is thought to recruit protein complexes which
enforce either active or inactive transcriptional states, and thus perpetuate transcriptional
memory (Kouskouti and Talianidis, 2005; Lorentz et al., 1994; Nakayama et al., 2001;
Ogawa et al., 2002; Peters and Schubeler, 2005; Stewart et al., 2005).
The complexity of histone modifications and their recognition by specific effector
modules led to the proposal that these modification/recognition systems constitute a
“histone code”, defined as a system in which “multiple histone modifications, acting in a
combinatorial or sequential fashion on one or multiple histone tails, specify unique
downstream functions” (Strahl and Allis, 2000). The existence of such a code is highly
controversial, since it is difficult to formally prove that multiple modifications occurring
after histone deposition on a single histone tail are distinguished combinatorially
(Henikoff, 2005), as predicted by the model. What is clear, however, is that histone
modifications can have profound effects on gene expression, and that some cross-talk
between modifications is possible, as with the previously discussed example of
recognition of dual-modified H3 by CMT3.

1.3 Methylation of non-histone targets
Recent reports have begun to expand the “language” of covalent histone modifications
to non-histone proteins. It has been known for some time, for instance, that proteins
other than histones can be acetylated by canonical HATs (Chan and La Thangue, 2001;
Imhof et al., 1997). Most of the other known modifications of histones (phosphorylation,
ubiquitination, ADP-ribosylation etc.) have similarly been well characterized to occur on
non-histone proteins. Similarly, arginine methylation is known to exist on numerous
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proteins, many of them transcriptional regulators or proteins involved in translation
(Blanchet et al., 2005; Lee et al., 2005a; Miranda et al., 2005; Strahl et al., 2001; Teyssier
et al., 2005; Tidwell et al., 1968). Until recently, the only exception was lysine
methylation, which had been poorly studied outside of histones. Although reports of
protein lysine methylation have existed for over thirty years (Allfrey et al., 1964; Paik
and Kim, 1971), the identification of both the targets of methylation as well as the
enzymes that modify them remained elusive.
Recent years have seen significant progress, beginning with the observation that the
basal transcription factor TAF10 is lysine methylated, and that this methylation is carried
out by the SET9 methyltransferase (Kouskouti et al., 2004). SET9 was previously
described as a H3K4-specific enzyme, which was proposed to facilitate transcription both
through methylation of H3K4, as well as through an inhibitory effect of H3K4
methylation on methylation of H3K9 (Chuikov et al., 2004; Nishioka et al., 2002).
TAF10 monomethylation was shown to increase interaction of TAF10 with RNA
Polymerase II, thereby potentiating transcription of target genes. This finding was
consistent with initial studies indicating that SET9 could stimulate transcription, despite
the fact that nucleosomal histones were poor in vitro substrates for SET9-mediated
methylation (Nishioka et al., 2002).
Subsequent experiments have demonstrated that TAF10 is not the only non-histone
target of SET9 methyltransferase activity. It was recently shown that the critical tumorsuppressor protein p53 also undergoes lysine monomethylation, and that this methylation
is mainly carried out by SET9 (Chuikov et al., 2004). Methylated p53 was strictly
nuclear, and was stabilized relative to unmethylated p53, suggesting a possible increase
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in transactivation activity. Indeed, methylated p53 could be detected by chromatin
immunoprecipiation (ChIP) at the p53-responsive p21 promoter after treatment of cells
with adriamycin, although the relative affinity of methylated versus unmethylated p53 for
promoter binding was not examined. As p53 is known to be subject to myriad posttranslational modifications (Yang, 2005), it is possible that methylation may influence the
presence and/or absence of these other marks as well.
The most recently reported non-histone target of lysine methylation is the yeast
kinetochore protein Dam1 (Zhang et al., 2005). Dam1 was found to be methylated on
multiple lysines, and this methylation was greatly reduced, but not eliminated, by
mutation of the H3K4 methyltransferase Set1. Set1 itself is best known for its role in
transcriptional activation through interaction with the RNA Pol II holoenzyme, via the
Paf1 complex (Briggs et al., 2001; Roguev et al., 2001; Tenney and Shilatifard, 2005).
Zhang et al. also demonstrated that lysine methylation of Dam1 reduces the ability of Ipl1
(the endogenous H3S10 kinase) to phosphorylate an adjacent serine, possibly suggesting
a functional crosstalk between the two sites. However, the physiological relevance of
these findings are questionable, since while mutation of a single methylation site in Dam1
is lethal, deletion of Set1, the enzyme claimed to be responsible for carrying out the
methylation, has no effect on cell viability (Zhang et al., 2005).
Overall, three important points stand out from the existing data on non-histone lysine
methylation. To begin with, all three of the proteins discussed above (TAF10, p53 and
Dam1) are involved directly in transcriptional control or chromosome function. While
this could be due to chance (considering the small number of non-histone targets
identified to date), it is also possible that the pool of lysine methylated proteins is
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inherently enriched in chromatin-associated proteins. Such enrichment in particular
cellular compartments is plausible, considering that a large fraction of the arginine
methylated proteins identified previously in an unbiased mass-spectrometry based
analysis were unexpectedly found to be cytoplasmic proteins involved in translation (Ong
et al., 2004).
The second important point is that the enzymes that methylate non-histone proteins
are the same enzymes that methylate histones. The mouse genome encodes for
approximately 55 SET-domain containing proteins (SCS, unpublished observation), only
a small number of which have been characterized to date. Thus, it was formally possible
that histone and non-histone methylation were carried out by separate groups of enzymes;
however, this does not seem to be the case. An important implication of this is that
mutant phenotypes for histone methyltransferases studied to date must be interpreted with
caution, as they may reflect loss of both histone and more general protein methylation
functions.
Finally, it is striking that none of the methylation sites identified to date bear any
similarity to known target sites in histones (Chuikov et al., 2004; Kouskouti et al., 2004;
Zhang et al., 2005). This is certainly surprising, given the remarkable target specificity of
histone methyltransferases in general. The fact that targets sites in histones and nonhistones are so dissimilar raises important questions about whether the fundamental
tenets of the histone code will be generally applicable to all proteins, or whether they are
unique to histones.
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1.4 Lymphocyte development
In adult mammals, the development of B and T lymphocytes begins in the bone
marrow, where common lymphoid progenitors (CLPs) reside. B cell development
continues further in the bone marrow, whereas T cell precursors migrate to the thymus,
where their development is completed. B cell development is a complex program, during
which clonal antigen specificity is produced through the process of V(D)J recombination.
The earliest steps of this process are carried out in progenitor (pro) B cells, in which
recombinational coupling of diversity (D) to joining (J) segments occurs biallelically at
the immunoglobulin heavy chain (IgH) locus. Successful completion of D-J joining is
followed by monoallelic V-DJ joining, ultimately producing functional heavy chain of
the µ isotype (IgH µ). The expression of membrane-bound µ chain in combination with
surrogate light chain (SLC, comprised of λ5 and v-pre-B subunits) and various signaling
components constitutes a functional pre-B cell receptor (pre-BCR), which signals clonal
expansion, allelic exclusion at IgH (preventing further V-DJ recombination), and V-J
recombination at the Ig light chain (IgL). Synthesis of complete surface IgM (IgH + IgL)
signals the cessation of V(D)J recombination and the testing of immature B cells for both
signaling capacity (positive selection) and autoreactivity (negative selection). Only
newly produced B cells which have correctly rearranged Ig loci and display little
reactivity towards self-antigens are stably selected into the peripheral population of
mature, naïve B cells.
Whereas naïve B cells are marked by expression of surface IgM and IgD, antigenactivated B cells produce Ig of other functional classes, known as isotypes. Isotype
switching is accomplished through the process of class switch recombination (CSR),
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which, similar to V(D)J recombination, is a lymphocyte-specific, developmentally
programmed DNA elimination event. In contrast to V(D)J recombination, however, the
purpose of DNA rearrangement in this context is not to generate antigen specificities, but
to alter the functional class of immunoglobulin produced by activated cells (IgA, IgG,
IgE, etc.). This is accomplished by altering constant chain (CH) usage via a deletional
mechanism. CSR is initiated when naïve peripheral B cells are activated in the
appropriate cytokine and cellular context, which together act to initiate transcription from
cytokine-responsive promoters (I regions) upstream of the target switch (S) regions
(Snapper et al., 1997). Transcription of the switch region corresponding to the target CH
is an invariant feature of CSR, and is required for efficient switching (Gu et al., 1993;
Jung et al., 1993). After transcription has begun, the excision of Cµ/Cδ is accomplished
by recombination between Sµ and the target switch region, releasing the intervening
DNA as an episome (Iwasato et al., 1990). S regions have a highly unusual sequence
composition, consisting mainly of repetitive and palindromic elements (Davis et al.,
1980; Shimizu et al., 1982). This finding has fueled speculation that higher order
structures produced during S region transcription might contribute to the specificity of
DNA breakage at these sites during CSR (Kinoshita and Honjo, 2001; Ramiro et al.,
2003; Shinkura et al., 2003).
While V(D)J and class switch recombination share many features in common,
including transcription of target sequences, dependence on cytokine signaling for
specificity, and restriction to particular developmental stages, they also differ in several
significant respects. Most importantly, while CSR and the process of somatic
hypermutation (SHM), a targeted mutagenesis program which results in increased
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antibody affinity, are strictly dependent on the activity of the recently-discovered
Activation-Induced cytidine Deaminase (AID), V(D)J recombination is not (Muramatsu
et al., 2000). While the exact role of AID in control of CSR and SHM remains highly
controversial, the dispensability of AID for V(D)J recombination strongly suggests basic
mechanistic differences between this process and CSR. Conversely, while V(D)J
recombination is completely dependent on activity of the Recombinase Activating Genes
(RAG), CSR is not (Rolink et al., 1996). Finally, the sequence of Recombination Signal
Sequences (RSSs), the recognition sites for the RAG recombinase during V(D)J
recombination, bears no resemblance to that of S regions, suggesting that while RAGs
may act as sequence specific endonucleases, S regions may rely on more general
structural features to accomplish targeting during CSR.

1.5 Histone modification in the immune system
Several data point to a role for histone modification in the control of B cell
development. For instance, while it has been recognized for some time that transcription
of target loci precedes DNA rearrangement during V(D)J recombination (Sleckman et al.,
1996), it was recently demonstrated that this developmentally programmed shift in
transcriptional activity and recombinase accessibility is correlated with increased local
levels of histone acetylation (Chowdhury and Sen, 2001; McMurry and Krangel, 2000).
Moreover, D and J(H) segments were found to be acetylated earlier than V(H) segments,
mirroring the order of recombination events at IgH. These findings suggest that at the
molecular level, the established concept of “locus accessibility” might be defined by
differential patterns of histone modification.
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This possibility is supported by data suggesting that accessible D and J loci in both T
and B cells are associated with diMeH3K4 and a lack of phosphorylation of H4 serine 1
(Morshead et al., 2003). Furthermore, recombinationally active gene segments are also
enriched in H3K79 methylation, a mark placed by the single known non-SET domain
HMTase, Dot1 (Feng et al., 2002; Ng et al., 2003). In contrast, recombinationally
inactive loci are enriched in H3K9 methylation (Morshead et al., 2003), which in B cells
is specifically removed in a process requiring the critical B cell lineage transcription
factor Pax5 (Johnson et al., 2004). These findings are summarized in Figure 1.4.

Figure 1.4 Patterns of histone modification on active and inactive
antigen receptor loci. Abbreviations: P, phosphorylation; Me,
methylation; Ac, acetylation; K, lysine. Adapted from Margueron et al.
(2005).
A possible link between locus accessibility and particular histone modification
patterns was further supported by the observation that 3’ V(H) genes, which are
preferentially utilized early in B cell development, are acetylated prior to 5’ V(H)
segments (Chowdhury and Sen, 2001; Yancopoulos et al., 1984). In addition, 5’ V(H)
genes were found to be hyperacetylated specifically in response to interleukin-7 (IL-7),
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correlating well with the observation that mice lacking IL-7Rα have defects specifically
in usage of 5’ V(H) genes, and that these defects are associated with a lack of germline
transcripts corresponding to these segments (Chowdhury and Sen, 2001; Corcoran et al.,
1998).
Strikingly, it was recently found that mice lacking the H3K27-specific histone
methyltransferase Ezh2 harbor very similar defects in variable chain usage to those
observed in IL-7Rα mice, despite any discernible effect of Ezh2 deficiency on IL-7
signaling per se (Su et al., 2003). The defect in 5’ V(H) usage in Ezh2-null mice was, in
fact, even more specific than in IL-7Rα-null mice, since germline transcription of these
sequences was not altered by loss of Ezh2 function. This finding suggests the possibility
that while histone acetylation may regulate locus accessibility broadly defined, histone
methylation may be responsible for recombinase targeting itself (Su et al., 2003).
Together, the existing studies on histone methylation and acetylation strongly imply that
histone modification may be a key regulatory pathway in lymphocyte development, and
that ordered recruitment of various histone-modifying activities may underlie the
exquisite specificity of DNA recombination reactions in lymphocytes.
The hypothesis that histone methylation may “mark” target sequences during DNA
rearrangement events in the immune system is supported by a similar function of histone
methylation in the unicellular eukaryote Tetrahymena thermophila. This organism is
unique in that it contains two nuclei: the germinal micronucleus is transcriptionally silent
and responsible only for transmission of genetic information during mating (called
conjugation), while the somatic macronucleus is transcriptionally active and responsible
for the phenotype of the cell, but is lost during mating. The process of conjugation

15

between cells of compatible mating type involves serial meiotic and mitotic division of
each micronucleus, reciprocal transfer of haploid pronuclei, pronuclear fusion to form a
zygotic micronucleus, and production of a new macronucleus from the zygotic
micronucleus. During development of the new macronucleus, thousands of interspersed
genetic elements, termed Internal Eliminated Sequences (IESs), are removed from the
genome through a deletional process (Coyne et al., 1996). Recently, it was found that
this DNA elimination program is tightly correlated with H3K9 methylation of histones
associated with DNA destined for elimination, and that “tethering” to ectopic sites of a
chromodomain protein which recognizes the methyl-lysine mark (Pdd1p) was sufficient
to promote deletion (Taverna et al., 2002). Likewise, disruption of parental Pdd1p was
found to interfere with DNA deletion (Coyne et al., 1999; Madireddi et al., 1996).
The similarities between programmed DNA elimination in Tetrahymena and processes
in the immune system, such as V(D)J recombination and CSR, are numerous. Both
nuclear downsizing and CSR, for instance, are developmentally programmed, depend
upon transcription of target sequences, and occur at sites marked by irregular repetitive
elements. Similarly, DNA elimination in Tetrahymena has been reported to coincide
with bidirectional transcription of the sequences to be eliminated, and processing of these
transcripts to form small RNAs capable of guiding DNA elimination (Chalker et al.,
2005; Chalker and Yao, 2001; Mochizuki et al., 2002; Mochizuki and Gorovsky, 2004;
Yao et al., 2003). Remarkably, a recent report indicated that V(D)J recombination at the
Ig heavy chain locus is also associated with production of antisense intergenic transcripts,
which might be capable of being further processed via an RNAi-like mechanism (Bolland
et al., 2004). Considering that H3K9 methylation is required for DNA elimination in
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Tetrahymena (Liu et al., 2004), it is possible that DNA modification programs in the
immune system, such as V(D)J recombination and CSR, might also be guided by H3K9
methylation.
In addition to its possible role in providing specificity for particular processes in B cell
development, H3K9 methylation may hold more general meaning for the function of
peripheral lymphocytes. In their normal unactivated state, naïve B and T cells are nonproliferative and have limited lifespan. Conversely, spontaneous activation and
proliferation of these cells in the absence of appropriate stimuli is pathogenic, and thus
associated with autoimmune disease. Recently, it was demonstrated that a transcriptional
complex capable of repressing E2F, Myc and Brachyury-responsive promoters is
specifically active in quiescent cells (Ogawa et al., 2002). Strikingly, this complex was
found to contain the human homologs of the related H3K9-specific methyltransferases
G9a and Eu-HMTase (also known as G9a-like protein, GLP). These proteins have now
been shown to associate with multiple transcriptionally repressive complexes, and are
thought to be the dominant HMTases mediating MeH3K9-dependent repression in
euchromatic chromosomal domains (Ogawa et al., 2002; Shi et al., 2003; Tachibana et
al., 2002). This conclusion is consistent with the embryonic lethality caused by complete
loss of G9a or GLP function (Tachibana et al., 2002; Tachibana et al., 2005).

1.6 Hypothesis and goals of this study
Based on the observations mentioned above, we propose that G9a and GLP may be
involved in the transcriptional repression of cell-cycle associated genes in quiescent,
naïve lymphocytes. Moreover, multiple lines of evidence point to the possibility that
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H3K9 methylation might play a role in guiding DNA recombination reactions in
developing lymphocytes. Should this be the case, the proven importance of G9a and
GLP for proper euchromatic H3K9 dimethylation make them excellent candidates for
carrying out this function, as well. Taken together, it is clear that significant insight into
the functions of histone methylation in the immune system could be gained through
production of mutants lacking G9a or GLP function. Since complete deletion of either of
these genes in the mouse is lethal (Tachibana et al., 2002; Tachibana et al., 2005), we
chose to investigate these issues further by producing conditional knockout alleles of G9a
and GLP.
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CHAPTER 2: MATERIALS AND METHODS
2.1 Cloning of targeting constructs
For isolation of the G9a genomic clone, a BAC (RPCI24-165L4; BL/6; CHORI,
Oakland CA, USA) containing the murine G9a locus was obtained. This was digested
with a cocktail of enzymes to release a ~10kb fragment containing the entire region
containing the long and short arms of homology, which was subcloned into
pBlueScriptIIKS+. This was partially digested with SapI, and an annealed doublestranded oligonucleotide containing the upstream loxP site and a HindIII site was
inserted. The vector was then digested with BsaBI, and a NsiI fragment from pZeroloxP-FRT-neo-FRT(-) (D. O’Carroll, Rockefeller University) containing the downstream
loxP site and FRT-flanked neo gene was inserted and screened for proper orientation.
The resulting plasmid was digested with NheI and AflII to release the targeted locus,
which was inserted into XhoI-digested pDTA-TK (D. O’Carroll, Rockefeller University)
to produce the final targeting construct.
The GLP genomic locus was recombinogenically subcloned from a BAC clone
(RPCI24-156K12; BL/6; CHORI, Oakland CA, USA) essentially as described (Yu et al.,
2000; Lee et al., 2001) into pBlueScriptIIKS+ using primers which inserted a 5’ AscI site
and 3’ FseI site. Briefly, EL350 cells were grown overnight in 5 ml of LB at 32C. 0.5-1
ml of the overnight culture was innoculated into 50ml of fresh LB in a 500ml flask and
grown at 32C with shaking to OD600 0.5-0.8. The cells were then shaken in an ice bath
slurry by hand to cool the sample down quickly. 10 ml of the culture was pelleted for 8
minutes at 7000 rpm (5500g) at 4C. The cell pellet was washed 3 times with 1 ml of cold
sterile water and resuspended in 100ul of ice-cold water for electroporation. 50 ul of

19

competent cells was transferred to pre-chilled electroporation cuvettes (0.1 cm Bio-Rad
Cat# 165-2089), 1 ug of freshly prepared BAC DNA was added and electroporated at
1.8kV on a Bio-Rad Gene Pulser set at 25uF and 200 ohms. 1 ml of LB medium was
added to the cuvette and transferred to an eppendorf tube, incubated at 32C for 1-1.5
hours and plate on chloramphenicol plates.
To excise the genomic fragment by recombineering, the BAC-containing EL350 strain
was grown overnight in 5 ml of LB at 32oC. 0.5-1 ml of the overnight culture was
innoculated in 50ml of fresh LB in a 500ml flask and grown at 32C with shaking to
OD600 0.5-0.8. RED induction was performed by transferring 10 ml of the growing
culture into a 125ml conical flask in a water bath at 42C with shaking (200 revs/min) for
15 min. Immediately after induction, the flask was placed into an ice bath slurry and
shaken by hand to cool the sample. 10 ml of the culture was spun for 8 min at 7000 rpm
(5500g) at 4C, and the cell pellet washed 3 times with 1ml of cold sterile water. After the
final wash the cells were resuspended in 100 ul of ice-cold water, and 50 ul of cells was
transferred to a pre-chilled electroporation cuvette (0.1 cm). 100ng of pBS PCR amplicon
was added and electroporated at 1.8kV on a Bio-Rad Gene Pulser set at 25 uF and 200
ohms. 1 ml of LB medium was immediately added to the cuvette, transferred to an
eppendorf tube, and shaken at 32C for 1-1.5 hours before plating on ampicillin plates.
The properly recombined plasmid was digested with NheI, and an annealed doublestranded oligonucleotide containing the upstream loxP site and a BsrGI site was inserted.
The vector was then digested with BamHI, and a NsiI fragment from pZeroloxP-FRTneo-FRT(-) (D. O’Carroll, Rockefeller University) containing the downstream loxP site
and FRT-flanked neo gene was inserted and screened for proper orientation. The
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resulting plasmid was digested with AscI and FseI to release the targeted locus, which
was inserted into XhoI-digested pDTA-TK (D. O’Carroll, Rockefeller University) to
produce the final targeting construct.

2.2 ES cell methods and production of mice
Embryonic stem cell culture was performed as described (Torres and Kuhn, 1997)
using the ES cell line E14.1 (129/Ola). ES cells were cultured on embryonic feeder (EF)
cells in ES cell medium containing leukemia inhibitory factor (LIF). Both LIF
conditioned medium and EF cells harboring a neor-gene were prepared as described
(Torres and Kuhn, 1997). The batch of FCS used for ES cell culture was tested to yield
optimal plating efficiency without differentiation of ES cells. EF cells were passaged at
most four times and treated with Mitomycin C (Sigma) (10 µg/ml in EF cell medium) for
2 hours at 37C immediately before use for ES cell culture. To maintain their
undifferentiated state, ES cells were always passaged at a subconfluent stage. For
passaging, ES cells were washed twice with PBS and trypsinised at 37C for 1-3 minutes.
Trypsinization was stopped by adding 3-5 volumes of ES cell medium, followed by
pipetting to yield a single cell suspension. ES cells were passed at 1:10-1:20 dilutions.
Cells were frozen at –80C in ES cell medium containing 10% dimethylsulfoxide
(DMSO). After freezing, ES cells were transferred to liquid nitrogen for long term
storage.
All procedures concerning the manipulation of ES cells in vitro were performed as
described (Torres and Kuhn, 1997). Briefly, 1x107 ES cells were mixed with 25 µg of
linearised targeting vector DNA (0.5 µg/ml) in 0.8 ml PBS. Following transfection by
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electroporation (500 µF, 230V), ES cells were plated at 2x106 per 10 cm tissue culture
dish. G418 selection (350 µg/ml) for the presence of the neor-gene was started at 24 hrs
and gangcyclovir selection (2 µM; to select for absence of the TK gene) was started 5
days after transfection. The selection medium was changed daily. Between day 7-10
after transfection, G418/gangcyclovir resistant ES cell colonies were picked and
trypsinized. Cells were split in two, and half the sample used for PCR screening (see
below, “PCR”). Positive clones were serially expanded in EF coated 48, 12 and 6-well
plates subconfluently, and also plated at time of passage into 6 wells onto 6-well dishes
pre-coated with gelatin as described (Torres and Kuhn, 1997). ES cells grown in the
absence of feeders were used for Southern typing, while the cells grown on feeders in 6well dishes were frozen as described above.
Preparation of ES cells for blastocyst injection was done as described (Torres and
Kuhn, 1997). Injections were performed by the Rockfeller University Transgenics
Facility. Chimeric mice were crossed to BL/6 and assessed for germline transmission by
coat color. Deletion of the FRT-flanked neo gene was accomplished by crossing to
eFLP-transgenic mice (Rodriguez et al., 2000). Routine typing was performed by tail
biopsy and PCR.

2.3 Mice
Mice were maintained in the Rockefeller University Laboratory Animal Resource
Center under Specific Pathogen Free (SPF) conditions. All procedures were approved by
the Institutional Animal Care and Use Committee (IACUC). G9a and GLP mice were
maintained on a mixed BL/6-129 genetic background.
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2.4 Genomic DNA isolation
For analysis of targeted mice, genomic DNA was isolated from single cell suspensions
of total splenocytes. ~1X108 cells were lysed in 0.5 ml tail lysis buffer [10 mM TrisHCl pH8.5, 5mM EDTA, 0.2% sodium dodecyl sulfate (SDS), 200 mM NaCl, 100 µg/ml
proteinase K] at 55°C over night. After centrifugation at 15,000g for 10 min, the
supernatant was transferred to a fresh 1.5 ml reaction tube. 1 ml 100% ethanol was added
and shook vigorously. The precipitate was spun for 5 min at 15,000g, washed once in
70% ethanol and briefly air dried. Samples were resuspended in 100-500 µl 10 mM TrisHCl pH 8.0. For analysis of ES cells, pelleted cells were lysed directly in tail lysis buffer
and processed as described above.

2.5 Genomic DNA digestion
For standard Southern blot analysis, 15 ug of genomic DNA prepared as described
above was digested overnight in a 50 ul reaction with 100 units of the appropriate
enzyme in 1X reaction buffer (all enzymes and buffers from NEB). After overnight
digestion, 20 units of enzymes were added and the reaction continued for a further 2
hours. Reactions were stopped with 1X Orange G loading buffer for electrophoresis.
For analytic restriction digests, 5-10 fold excess of enzyme was used to digest DNA
for 1 hour at 37C per manufacturers protocol (all enzymes purchased from NEB) before
stopping with loading buffer.
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2.6 Southern blotting
DNA was electrophoresed on either 2% (for RT-PCR products) or 0.8% (for genomic
DNA) agarose gels and rotated in transfer buffer (0.6 M NaCl, 0.4 M NaOH) for 45 min.
DNA was transferred by upward capillary transfer onto Hybond-N membrane
(Amersham) overnight. Blots were rotated in neutralization buffer [0.5 M Tris-HCl (pH
7.0), 1 M NaCl] for 15 min and crosslinked in a Stratalinker (Stratagene) on “auto” mode.
Blots were incubated briefly in 2XSSC, and transferred into pre-warmed hybridization
buffer [50 mM Tris-HCl (pH 7.5), 1 M NaCl, 1% SDS, 10% dextran sulfate, 300 ug/ml
sonicated salmon sperm DNA] and pre-hybridized for 3 hours at 65C.
Probes were PCR amplified from 0.01-0.1 ng BAC DNA and gel purified (Qiagen).
DNA (50 ng) was labeled with 5 ul 32P-α-dCTP using Ready-to-Go labeling beads
(Amersham) and purified over ProbeQuant G50 spin columns per manufacturers
protocol. Eluted DNA was boiled for 5 min and iced for 5 min prior to addition to prehyrbidized blot. Hybridization was carried out overnight at 65C. Blots were washed
twice for 10 min each in 2XSSC/0.1% SDS, 1XSSC/0.1% SDS and 0.5XSSC/0.1% SDS,
wrapped in SaranWrap and exposed to film (Kodak XAR).

2.7 RT-PCR and oligonucleotide Southern blot
A maximum of 5X106 cells were lysed in 1 ml Trizol (Gibco) and total RNA was
prepared per manufacturers protocol. GlycoBlue coprecipitant (Ambion) was added to
50 ug/ml before isopropanol precipitation. 1 ug total RNA was reverse transcribed using
oligo(dT) primer (Invitrogen) and SuperScript III reverse transcriptase (Invitrogen) per
manufacturers protocol. 1 ul first strand cDNA was used for PCR amplification in a 20
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ul reaction volume with the appropriate primers as detailed under “General PCR”.
Southern blots were performed as described under “Southern blotting” with the following
modifications. Oligonucleotide probes (20 pmol) were labeled with 5 ul 32P-γ-ATP in a
20 ul reaction using T4 Polynucleotide Kinase (NEB) and purified over ProbeQuant G25
spin columns (Amersham) per manufacturers protocols. Hybridization was performed at
50C overnight and washed/exposed as described under “Southern blotting”. When
needed, blots were exposed on a PhosphorImager screen (Amersham) and quantitated
using ImageQuant software.

2.8 PolyI:C treatment
For induction of deletion in mice carrying the MX-cre transgene, mice were injected
twice (separated by 72 hr) intraperitoneally with 200 ug polyI:C (Amersham). polyI:C
was prepared by dissolving solid powder in sterile DPBS, heating at 56C for 3 hours and
cooling slowly to room temperature. The dissolved polyI:C was sterile filtered and stored
in aliquots at –20C.

2.9 FACS analysis
For routine FACS analysis of lymphocytes, mice were sacrificed by CO2 euthanasia
and organs collected sterilely. For splenocytes and thymocytes, single cell suspensions
were prepared by scraping through a sterile plastic mesh in Hanks Balanced Salt Solution
(BSS) with phenol red. Erythrocytes were lysed in 1 ml per spleen erythrocyte lysis
buffer (0.75% NH4Cl, 100 mM Tris/HCl pH 7.65) for 3 min at room temperature, and
the lysis stopped by addition of 10 ml cold BSS. 5X105 cells were used per staining,
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which was performed in U-bottom 96 well plates (Corning). Cells were stained in 15 ul
BSS with antibody at the concentration listed below for 20 min at 4C , washed once with
BSS and either stained with secondary antibody or resuspended in BSS with 2 nM ToPro3 (Molecular Probes) for FACS.

2.10 Antibodies
FACS antibodies (all purchased from BD Pharmingen unless otherwise noted)
α-mouse CD19 (clone 1D3) FITC 1:100; α-mouse CD4 (clone GK1.5) PE 1:200; αmouse CD43 (clone S7) FITC 1:100; α-mouse CD8 (clone 53-6.7) FITC 1:100; α-mouse
CD90.2 (clone 53-2.1) PE 1:400; α-mouse IgD (clone 11-26C.2a) FITC 1:100; α-mouse
IgM (clone 711116152) PE 1:300 (Jackson lab); α-B220 Cychrome (1:75).
Western blot/immunoprecipitation antibodies
αG9a (RU1061), rabbit, 1 ug/ml; α4xdiMeK9 (kind gift of T. Jenuwein, IMP,
Vienna), rabbit, 6 ug/ml; αTubulin (source unknown), mouse, 1:5,000; αFLAG M2
(Sigma), mouse, 10 ug/ml; αdiMeG9aMS2 (RU1218), rabbit, 2 ug/ml; αLamin B (Santa
Cruz Biotech), goat, 1:500; αHP1γ (Upstate), rabbit, 1:500; αHP1α (Upstate), rabbit,
1:500; αGLP (RU1160), rabbit, 1 ug/ml; αdiMeH3K9 (Upstate, #07-212), rabbit, 1:500.

2.11 PCR
For routine PCR (typing, etc) 1 ul sample was used in a 20 ul reaction containing 1X
KlenTherm buffer [67 mM Tris-HCl (pH 9.1), 16 mM ammonium sulfate, 2.5 mM
MgCl2, 150 ug/ml BSA], 2.5 mM each dNTP, 0.4 uM each primer and 1 unit Taq
polymerase (Sigma). Typing PCR conditions: 94C, 2 min; 94C, 1 min; 65C, 1 min, 72C,
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1 min; 35 cycles. For ES cell screening PCR, PlatinumTaq (Amersham) was substituted
in the reaction, and 42 cycles of amplification were performed.

2.12 PCR primers

Primer name

Sequence

Purpose

G9a type 1

TGCAGACTCTGCACCTTGCTCTTCTG

G9a typing

G9a type 2

GTGTGAGCCTGTGTTCTGGGGATTA

G9a typing

G9a type 3

CCGGAGATGAGGAAGAGGAGAACAG

G9a typing

GLP type 1

GGGTTGTGCTCAGAGTTTCTACCTC

GLP typing

GLP type 2

TCCCTCATCGCCCACATTTCTG

GLP typing

GLP type 3

CCGGAGATGAGGAAGAGGAGAACAG

GLP typing

G9a Probe G

GGGCTCCTGGGCTCTATGAG

G9a probe G

ATCAGCTGGCAGAGGCCCAAC

G9a probe G

Probe E FWD

CGGGATCCGGACGTAGCCCGAGGCTATGAG

G9a probe E

Probe E REV

CGGGATCCCTTGTCATACCAGCATCGGATAC

G9a probe E

Probe 18-19

CCTCTTTCTTTCTCGGGATTCAG

GLP probe A

CTGCAAATGAGTGATGTTCCTG

GLP probe A

CCTGTTAAACATGGCTGCTTG

GLP probe B

FWD
G9a Probe G
REV

FWD
Probe 18-19
REV
LAH extl probe
FWD (should be
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SAH)

FWD (should be
SAH)
LAH extl probe

TTCTCTTTTTCCTTGTCTGCCC

GLP probe B

AACCAGTCAACACCCTTCC

CD19cre

REV (should be
SAH)
CD19C

typing
CD19D

CCAGACTAGATACAGACCAG

CD19cre
typing

CRE7

TCAGCTACACCAGAGACGG

CD19cre
typing

MX CRE F

CATGTGTCTTGGTGGGCTGAG

MXcre typing

MX CRE R

CGCATAACCAGTGAAACAGCAT

MXcre typing

SD24

CTAATGTTGTGGGAAATTGGA

FLPer typing

SD25

CTCGAGGATAACTTGTTTATTG

FLPer typing

Table 2.1 PCR Primers used in this study. All sequences are given 5’-3’.

2.13 B cell purification
Splenic B cells were purified using α-CD43 microbeads (Miltenyi Biotec) per
manufacturers protocol. Purity as judged by B220 staining was consistently >90%.
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2.14 CFSE labeling and B cell stimulation
Purified splenic B cells were washed twice in plain RPMI and resuspended at 1X107
cells/ml in plain RPMI with 2.5 µM carboxyfluoroscein diacetate succinimidyl ester
(CFSE; Molecular Probes). After incubation at 37C for 10 min, 10 ml cold serum was
added and cells were washed twice with complete medium [RPMI 1640, 10% Fetal
Bovine Serum, 1X Penicillin/Streptomycin (Gibco), 1X L-Glutamine (Gibco), 50 uM
betamercaptoethanol] before resuspension in complete medium for cell culture. 2x105
cells were cultured per well of a 96-well flat bottom plate for 3-4 days in complete
medium with varying stimuli at the following concentrations: α-F(ab)2 of IgM (1-5
µg/ml), rIL-4 (25 U/ml), LPS (5 µg/ml).

2.15 Protein lysate preparation
For routine protein lysate preparation, cells or purified nuclei were resuspended in an
appropriate volume M2 lysis buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM
EDTA, 1% Triton X-100) with 1X protease inhibitor cocktail (Sigma) and rotated at 4C
for 30 min. After centrifugation at 14000 rpm for 15 min at 4C, the supernatant was
moved to a new tube and quantitated by Bradford assay (Biorad). 50 ug of lysate were
typically loaded per lane.

2.16 Western blotting
Gels were blotted in a submerged transfer chamber (Biorad) in 1X transfer buffer [48
mM Tris-HCl, 39 mM Glycine, 0.037% (w/v) SDS, 20% MeOH] overnight at 15 volts,
4C, onto 0.2 micron pore nitrocellulose (Schleicher and Schuell). Membranes were
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stained with Ponceau S (Sigma) and destained with dH2O before cutting individual strips
for probing. Strips were blocked 1 hr at room temperature with 4% autoclaved milk in
PBS. Antibodies (see separate list for concentrations) were diluted in block and added
for 1 hr at room temperature. For all antibodies except FLAG M2, blots were washed 4
times 5 min in PBS/0.1% Tween 20 (PBST). For FLAG M2 blots, washing was done
twice for 5 min in PBS. All secondary anibodies were used at 1:10,000 dilution in block,
and all blots were washed 4 times 5 min in PBST. Detection was performed with ECL
(Amersham) or Visualizer (Upstate) as required.

2.17 Peptides
All G9a peptides were produced by the Rockefeller University Proteomics Resource
Center and were at least 85% pure. G9a MS2 peptides all included a C terminal cysteine
and contained the base sequence KVHRARKTMSKPGC. H3 peptides were kindly
provided by C.D. Allis (Rockefeller University).

2.18 Calcium phosphate transfection
For transfection of 1 10 cm dish, 5X106 293 cells were plated 1 day prior to
transfection, and the medium was changed the next day prior to transfection. 10 ug
plasmid DNA in 480 ul was mixed with 120 ul 1.25 M CaCl2 and added dropwise to 600
ul 2X HBS (pH 7.0) with gentle vortexing. After 30 min incubation at room temperature,
the precipitate was added dropwise to cells. Medium was replaced after 24 hr, and all
cells were harvested 48 hr after transfection.
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2.19 Nuclear fractionation
For fractionation of nuclei, 1X107 cells were collected by trypsinization, washed once
with cold DPBS, and resuspended in Buffer A [10 mM HEPES (pH 7.9), 5 mM MgCl2,
0.25 M sucrose]. NP-40 was added to 0.1% final concentration, the mixture pipetted
through an 18 guage needle 4 times, incubated at 4C 10 min, and spun 10 min at 8000
rpm, 4C. The supernatant was taken as the cytosolic fraction, and the pellet as the
nuclear fraction.

2.20 Histone methyltransferase assays
HMTase assays were performed essentially as described (Rea et al., 2000) with the
following modifications: reactions were scaled down to 20 ul volumes, using 2.5-5 ug
peptide per reaction. For assay on beads, immunoprecipitations from ~0.5-1X107
transiently transfected 293 cells were used per reaction. Samples were stopped with 4X
Laemmli buffer (to 1X final concentration) and separated by SDS-PAGE on 15%
acrylamide gels. After Coomassie staining and destaining in 30% MeOH/10% acetic
acid, gels were dried 1hr at 80C under vacuum before exposure to a PhosphorImager
screen (described above).

2.21 Immunoprecipitation
For small scale immunoprecipiation (IP) of FLAG-tagged protein, 20 ul packed
volume M2-agarose beads (Sigma) was washed extensively with M2 lysis buffer and
added to lysed protein samples (see above). Samples were rotated overnight at 4C,
washed 3 times with 0.5 ml lysis buffer and boiled in 1X Laemmli buffer.
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For large scale FLAG M2 IP and small scale IP using αG9a antibody, M-270 Epoxy
Dynabeads (FLAG) or Protein A Dynabeads (G9a; both from Dynal Biotech) were
coated per manufacturers instructions. 100 ul (FLAG) or 10 ul (G9a) beads were used
per IP, and washing was done as above. To elute FLAG protein for mass spectrometry,
Dynabeads were resuspended after washing in 250 ug/ml 3xFLAG peptide (Sigma) and
rotated for 1 hr at 4C. The supernatant was used for SDS-PAGE.
For coimmunoprecipitation of G9a with endogenous HP1γ, transfected 293 cells were
arrested for 12 hr with 2 mM thymidine (Sigma) in medium 24 hr after transfection. 18
hr later, the fresh medium containing 20 uM MG-132 (Peptides International) was added,
and this was left on the cells until harvesting.

2.22 Antibody generation
For generation of αG9a antibody, residues 1-281 of murine G9a were fused to GST in
pGEX-6P-1. Protein production in transformed bacteria (E. coli BL21) was induced with
1 mM IPTG (Sigma) for 3 hr at 37C. Cells were lysed by sonication in lysis buffer (PBS,
1 mM EDTA, 1 mM EGTA, 1X protease inhibitor cocktail) and clarified by
centrifugation. The supernatant was passed over a Glutathione-Sepharose column
(Amersham Pharmacia Biotech), the column washed extensively with PBS and eluted
with excess glutathione per manufacturers protocol.
GST-G9a antigen was coupled to KLH and used to immunize rabbits by Cocalico
Biologicals. Sera were screened by Western blot against the immunizing antigen and a
highly reactive serum (RU1061) was affinity purified against immobilized antigen on
AffiGel 10 (Biorad) per manufacturers protocol. Peak fractions were pooled, dialyzed
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against PBS/50% glycerol and stored at –80C. For peptide antibodies, affinity
purification was performed by immobilization of peptides via a C-terminal cysteine on
SulfoLink coupling gel (Pierce) per manufacturers protocol. Peak fractions were
dialyzed and stored as above.

2.23 Peptide dot blots
For dot blots, 2 ul 0.5 mM peptide solution was spotted on pre-wetted moist
nitrocellulose (0.2 micron pore, Scheicher and Schuell). Blots were dried overnight at
room temperature before use, and were processed as described under “Western blotting”.

2.24 Peptide pulldown assays
G9a peptides were coupled to SulfoLink beads (Pierce) per manufacturers protocol.
25 ul (bed volume) beads were added to nuclear extracts prepared in M2 lysis buffer and
rotated overnight at 4C. Beads were washed 3 times in 0.5 ml lysis buffer and boiled in
1X Laemmli sample buffer.
Binding to in vitro translated proteins was performed essentially as described (Lachner
et al., 2001). Where necessary, peptides were dephosphorylated with 25 units PP1 (NEB)
for 30 min per manufacturers protocol. Samples were electrophoresed on 7.5-15% linear
gradient acrylamide gels, and stained with Coomassie blue, destained, dried and exposed
to PhosphorImager as described above.
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2.25 Adenoviral infection and subcloning
Cre-expressing adenovirus was a kind gift of I. Su (Rockefeller University).
Infections were carried out as described (Su et al., 2005). 2-3 passages after deletion,
cells were plated at 0.2 cells/well in 96 well plates and allowed to expand to confluence.
Wells showing growth were further expanded and tested for deletion. Two clones (#3
and #16) showing 100% deletion by PCR were selected for retroviral reconstitution. All
experiments were performed with derivatives of clone #3.

2.26 Retroviral infection
SV40-large T retrovirus was kindly provided by S. Buonomo (Rockefeller
University). FLAG-hG9a and mutations thereof were subcloned into pMSCV-Puro
(Invitrogen). For production of retrovirus, 7.5X105 BOSC packaging cells were plated in
1 well of 6 well dish and transfected 24 hr later with 1.4 ug retroviral vector and 0.6 ug
pCL helper plasmid using Fugene (Roche) per manufacturers protocol. 48 hr later the
supernatant was collected, passed through a 0.2 micron filter, and added directly to
subconfluent target cells in the presence of 20 mM HEPES and 10 ug/ml polybrene
(Sigma). 48 hr after infection, cells were selected by addition of medium containing 4
ug/ml puromycin (Sigma). Lines were subsequently maintained as bulk populations to
avoid integration site effects.

2.27 Indirect Immunofluorescence on Mouse Embryonic Fibroblasts
Cells were seeded into 6 well dishes containing acid washed, poly D-lysine (Sigma)
coated coverslips at 1x105 cells per well. After 12-18 hr, the medium was removed, the
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coverslips were washed twice with PBS at room temperature, and were fixed 10 min at
room temperature in freshly prepared 4% parafomaldehyde/PBS. Coverslips were then
washed twice in PBS, permeabilized with 0.5% Triton-X 100/PBS for 10 min at room
temperature, washed twice with PBS, and blocked overnight at 4°C in PBS/5% skim
milk/0.2% Tween 20. For detection, the coverslips were washed four times with AbDil
(TBS/0.1% Triton-X 100/2% BSA) and incubated for 1 hr at room temperature with
affinity purified αG9a (RU1061, 2 µg/ml), αHP1γ (2355 µg/ml; AbCam #ab10480),
αdiMeH3K9 (1:200; Upstate #07-212), or control rabbit IgG (2 µg/ml) diluted in AbDil.
Coverslips were then washed 4 times with AbDil and incubated with Alexa 488(Molecular Probes), FITC- (Jackson), or X-Rhodamine-conjugated (Jackson) secondary
antibodies diluted in AbDil for 1 hr at room temperature, washed 4 times with AbDil,
incubated briefly with 0.25 µg/ml Hoechst 33258 in AbDil to counterstain DNA, washed
once with AbDil, and mounted in 90% glycerol/PBS.
Imaging was performed using a Carl Zeiss Axioplan 2 microscope equipped with a
Photometrics CoolSnap HQ cooled CCD camera, and controlled by MetaMorph software
(Universal Imaging). Images were processed with MetaMorph and Adobe Photoshop.

2.28 Kinase Assay
Preparation of Xenopus egg extracts, immunoprecipitation using αIncenp antibody
and Aurora B kinase assays were performed essentially as described (Sampath et al.,
2004; Ohi et al., 2004). 2.5 ug peptide were used per reaction and samples were
separated by SDS-PAGE, Coomassie stained, destained, dried and imaged as discussed
above.
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CHAPTER 3: GENERATION AND ANALYSIS OF G9A AND GLP MUTANTS
3.1 Domain structure and expression of G9a and GLP

Figure 3.1 Domain structure of G9 and GLP. Schematic domain structure of
murine G9a and GLP/EuHMTase-1. ANK, ankyrin repeat; SET, Su(var)3-9, E(z),
Trithorax domain; E, gluatmic/aspartic acid repeats.

G9a and GLP are SET-domain containing proteins of the Suv39 family, all of which
to date have been shown to act as H3K9-specific histone methyltransferases in vitro and
in vivo (Dillon et al., 2005). Both proteins contain a C-terminal SET domain, which is
responsible for enzymatic activity, as well as pre-SET and post-SET domains, which
contribute to catalysis (Figure 3.1;(Dillon et al., 2005; Tachibana et al., 2001; Tachibana
et al., 2002; Tachibana et al., 2005). Both G9a and GLP also contain 5-6 centrally
located ankyrin domains, whose functions are unknown (Figure 3.1). In contrast to the
high degree of sequence similarity between the C-termini of G9a and GLP (>65%
sequence identity), the amino termini of the two proteins are relatively poorly conserved
with one another (<35% sequence identity; data not shown). The lack of conservation in
this region is consistent with the absence of identifiable protein domains, the only
exception being a stretch of 27 consecutive glutamic and aspartic acid residues in G9a
(denoted “E” in Figure 3.1). Despite this poor conservation, small “islands” of sequence
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identity can still be identified in the amino termini of G9a and GLP (discussed further in
Chapter 4).
Homologs of both G9a and GLP can be found in most vertebrates, while G9a
homologs are also present in invertebrates, including Drosophila. Interestingly, in
addition to the domains found in vertebrates, Drosophila G9a also contains an aminoterminal AT-hook, a protein domain thought to be involved in direct binding to AT-rich
DNA sequences (data not shown). Strikingly, this AT-hook is embedded within one of
the microdomains of sequence conservation between vertebrate G9a and GLP homologs
(see Chapter 4).

Figure 3.2 RT-PCR analysis of G9a and GLP expression patterns. Total RNA was
extracted from the indicated tissues and amplified by RT-PCR with primers specific for
either G9a (A) or GLP (B), followed by Southern blotting and hyrbidization with a
transcript-specific internal probe. –DNA indicates no RT samples was added for PCR.
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In order to determine whether G9a and GLP might have functional roles in the
immune system, we first sought to examine the expression pattern of these genes in
various immune and non-immune cell types. Total RNA was extracted from five
different immune cell populations (total thymocytes, total bone marrow, CD4+ T cells,
CD8+ T cells and splenic B cells) as well as four control tissues (liver, kidney, heart and
testis). These samples were reverse-transcribed and PCR-amplified using primers
specific for either G9a, GLP or HPRT (loading control). The PCR products were
separated by agarose gel electrophoresis, Southern blotted, and hybridized with internal
probes specific for each transcript. As shown in Figure 3.2A and B, expression of G9a
and GLP was readily detectable in all cell types tested, and at approximately equal levels.
Expression of G9a was moderately increased in testis, but neither G9a nor GLP showed
any significant overexpression in immune cell types.

3.2 Generation of conditional G9a and GLP mutant mice
In order to produce genetic systems for understanding the physiological functions of
G9a and GLP, it was necessary to produce targeted deletions in these genes. Both G9a
and GLP have previously been disrupted by conventional gene targeting, resulting in total
loss of function and embryonic lethality beginning at approximately gestational day E9.5
(Tachibana et al., 2002; Tachibana et al., 2005). For this reason, it was necessary to
produce conditional mutations, which allow specific deletion of the target gene in
particular tissues, thereby bypassing the complication of premature lethality
(Lewandoski, 2001). In order to conditionally inactivate G9a, a targeting construct was
generated which contained exons 23 and 24 flanked by loxP sites (“floxed”; Figure 3.3).
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These two exons encode the last third of the pre-SET domain and first quarter of the SET
domain, respectively, both of which are necessary for catalytic activity (Tachibana et al.,
2001). Thus, deletion of these exons in vivo by Cre recombinase expression should cause
production of a catalytically inactive protein. In addition, Cre-mediated deletion is
predicted to cause out-of-frame splicing of exons 22 and 25, leading to nonsensemediated decay (NMD) of the mutant transcript. The targeting vector also contained a
neomycin-resistance gene (neo) for positive selection, as well as Thymidine Kinase (TK)
and Diphtheria Toxin (DTA) cassettes outside the arms of homology to allow negative
selection. The neo gene was flanked by FRT sequences (recognition sites for the FLP
recombinase), in order to allow removal of the selection cassette in vivo.

Figure 3.3 G9a conditional targeting strategy. Partial diagram of the G9a
genomic locus. Exons are indicated by unfilled rectangles, loxP sites by filled
triangles, FRT sites by shaded octagons, and the location of Southern probes by dark
rectangles. Restriction sites are abbreviated as follows: RI, EcoRI; B, BamHI; H,
HindIII.
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E14.1 ES cells (129/Ola genetic background) were electroporated with the G9a
targeting construct, and cells were selected for resistance to G418. Resistant colonies
were expanded and screened by Southern blot for proper targeting using probes G
(external to the short arm of homology) and E (internal to the long arm of homology).
Proper targeting was achieved in multiple clones (Figure 3.4A), and these were injected
by the Rockefeller University Transgenics facility into blastocysts from pseudopregnant
BL/6 female mice. Chimeric progeny were bred to BL/6 partners, and germline
transmission was obtained from a single male founder (derived from ES cell clones 1A4
and 1F10). Germline progeny were crossed to mice expressing the enhanced FLP
transgene (Rodriguez et al., 2000) in order to delete the neo cassette, leaving behind a
single scarring FLP site and the conditionally targeted locus (Figure 3B.1). Proper
deletion of the neo cassette was confirmed by Southern blotting of splenocyte DNA from
floxed (fl) mice (Figure 3.4B).
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Figure 3.4 Evaluation of G9a targeting by Southern blot. A. Genomic DNA
samples from the indicated ES cell clones were digested with HindIII and blotted
sequentially with probes E and G. B. Splenocyte DNA from progeny of the
indicated genotypes after neo cassette removal was digested with HindIII and
probed with probe G (left) or probe E (right). Probe E fragment sizes: WT, 7.3 kb;
Targeted (with upstream loxP site), 2.5 kb; Targeted (without upstream loxP site),
3.4 kb; Floxed, 2.5 kb. Probe G fragment sizes: WT, 7.3 kb; Targeted (with or
without upstream loxP site), 6.1 kb; Floxed, 4.8 kb.

Prior to conditional targeting of G9a with the loxP-FRT construct, we also attempted
to produce G9a mutants using the more traditional “three loxP” system, in which the neo
gene is flanked by loxP sites, and removed in ES cells after targeting by transient
transfection with a Cre-expressing plasmid. While proper targeting was achieved with
this construct, we were never able to derive heterozygously floxed ES cells, since
transient expression of Cre invariably drove complete recombination to produce the
deleted allele (data not shown). This was most likely due to the presence of an extremely
small floxed region in our targeting strategy (957 bp), making complete deletion highly
41

efficient. Nonetheless, this targeting did produce heterozygously deleted ES cells, which
we were able to use to examine whether the mutant transcript underwent NMD.

Figure 3.5 Nonsense-mediated decay of G9aΔ transcript. A. RT-PCR and Southern
blotting was performed on three-fold serial dilutions (1, 1:3, 1:9) of first-strand cDNA
from three G9aTarg/+ ES cell clones (13, 34, 51) and three G9aΔ/+ clones (13-2A, 51-9F,
51-11E). Expected band sizes: WT transcript, 509 bp; deleted transcript, 306 bp. B.
The results from A. were quantitated by PhosphorImager analysis and normalized to
HPRT values. Error bars represent the standard deviation for three clones.
Total RNA was extracted from three parental and three deleted ES cell clones, and
used for RT-PCR with primers spanning the deleted exons. After electrophoresis and
Southern blotting, the bands were quantitated by PhosphorImager analysis and
normalized to the HPRT control. While a smaller band corresponding to the deleted
transcript was not seen in the parental clones, such a band was readily seen with all three
heterozygously deleted clones (Figure 3.5A). Quantitation revealed that the deleted band
was present at only 10% the level of the wild type band in the deleted cells (Figure 3.5B).
Assuming biallelic transcription of G9a, this reduced abundance indicates that the mutant
transcript efficiently undergoes NMD.
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Figure 3.6 GLP conditional targeting strategy. Symbols are as described in Figure
3.3. Abbreviations: DTA, Diphtheria Toxin gene; neo, Neomycin resistance cassette;
TK, Thymidine Kinase gene.

The targeting strategy for GLP was very similar to that for G9a. The overall exonintron structure of the two proteins is well conserved (Dillon et al., 2005), making a
similar strategy feasible. The SET domain of GLP is encoded by exons 22, 23 and 24,
but deletion of exon 22 (corresponding to exon 23 of G9a) was not possible due to the
likelihood of subsequent in-frame splicing. Instead we chose to flox exon 23 of GLP
(corresponding to exon 25 of G9a), which encodes the second quarter of the SET domain,
and deletion of which should lead to out-of-frame splicing of exons 22 and 24 (Figure
3.6).
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Figure 3.7 Evaluation of GLP targeting by Southern blot. A. Genomic DNA
samples from the indicated ES cell clones were digested with BsrGI and blotted
sequentially with probes A and B. B. Splenocyte DNA from progeny of the
indicated genotypes after neo cassette removal was digested with HindIII and
probed with probe B. Probe A fragment sizes: WT, 10.2 kb; Targeted (with
upstream loxP site), 6.7 kb; Targeted (without upstream loxP site), 12.3 kb. Probe
B fragment sizes: WT, 10.2 kb; Targeted (with upstream loxP site), 5.5 kb;
Targeted (without upstream loxP site), 12.3 kb Floxed, 3.5 kb.
A loxP-FRT targeting construct was prepared for GLP in essentially the same manner
as for G9a. Proper targeting in ES cells was assessed by hybridization of Southern blots
of BsrGI-digested ES cell DNA with probes A (external to the long arm of homology)
and B (external to the short arm of homology). Correctly targeted ES cells (Figure 3.7A)
were injected into BL/6 blastocysts by the Rockefeller University Trangenics facility.
Germline transmission was obtained from several male chimeras, all derived from clone
1D7. These were bred to eFLP-transgenic mice to delete the neo cassette, leaving the
properly targeted floxed allele (Figure 3.7B).
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3.3 Analysis of G9a deletion in central lymphoid organs

Figure 3.8 Deletion of G9a in vivo with MX-cre. A. Strategy for deletion using
MX-cre. B. PCR analysis of genomic DNA harvested from the indicated tissues 10
days after the final polyI:C injection.

To begin to address the issue of the contribution of G9a to the development of
lymphocytes, we crossed the G9aflox allele to the MX-cre driver strain (Kuhn et al.,
1995). This strain carries Cre under the control of the interferon-responsive MX
promoter, which can be induced by intraperitoneal injection of mice with the doublestranded RNA mimic, polyI:C. G9afl/+ or G9afl/fl MX-cre+ mice were injected with 200
µg polyI:C twice over 72 hours, and sacrificed ten days later for analysis (Figure 3.8A).
Deletion of the G9a locus was first assessed by PCR typing of deleted tissues. As has
been observed with other conditional mutants using the MX-cre driver, deletion was
extremely efficient in both bone marrow and thymus, but incomplete in peripheral
lymphoid organs such as the spleen (Su et al., 2003).
We first examined B cell development in the bone marrow by flow cytometry. Proand pre-B cells can be distinguished from more mature B cell lineages in the bone
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marrow by expression of the CD45 glycosylation isoform B220 and their lack of surface
µ chain (IgM) expression (B220+IgM-). As cells complete V(D)J recombination to
produce a functional B cell receptor, they become surface IgM+ immature B cells. These
eventually emigrate to the peripheral lymphoid organs (spleen and lymph nodes), and
recirculate through the bone marrow as B220hiIgM+ cells. As shown in Figure 3.9 (left
upper and lower panels), the overall fraction of B220+IgM- pro- and pre-B cells was
unchanged in G9a-deleted mice ten days after the final injection of interferon.

Figure 3.9 Loss of G9a function causes a block in B cell development.
Mice of the indicated genotypes were sacrificed 10 days after the final
polyI:C injection and total bone marrow was stained as indicated and
analysed by FACS. B220/CD43 staining in the right-hand panels was
gated on IgM-B220+ cells as indicated in the left-hand panes.

In contrast, a clear reduction in the frequency of B220+IgM+ immature B cells was
noted, with a slight increase in the frequency of recirculating B cells. As B cells mature,
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they lose IgM expression and begin to express heavy chain of the IgD isotype due to
biased alternative splicing of the heavy chain transcript. The depletion of IgM+ immature
B cells was also apparent in stainings for IgM and IgD in bone marrow (Figure 3.9,
middle panels), where a corresponding increase in IgD+ was also noted. These cells
represent mature recirculating cells, most of which are likely to be undeleted (Figure
3.8B).
The block in development of B cells to the sIgM+ stage could reflect a defect either in
progression of pro-B cells to the pre-B cell stage, which depends upon successful heavy
chain recombination, or failure of pre-B cells to complete light chain recombination. The
precise location of this block can be determined by staining of the pro/pre-B cell
population with αCD43 antibody, which preferentially stains pro-B cells. This staining
revealed that the B220+IgM- population in G9a-deleted mice was dramatically enriched
in CD43+ cells, indicative of a block in pro-to-pre B cell development. This phenotype is
qualitatively very similar to the effect of deletion of the H3K27-specific histone
methyltransferase Ezh2 in bone marrow (Su et al., 2002), and also resembles the
phenotype of mice lacking a functional receptor for Interleukin 7 (IL-7), a key trophic
factor for pro-B cells (Corcoran et al., 1998).
A major concern in interpretation of lymphocyte developmental phenotypes is the
possibility that removal of key molecules in cells that are undergoing rapid rounds of cell
division (such as occur during development to the immature B cell stage) can have nonspecific toxic effects which may superficially appear quite specific. One way to address
this possibility is to examine the effect of loss of function on the development of other

47

cell lineages, such as T cells. We thus examined whether T cell development in the
thymus was affected by loss of G9a function.

Figure 3.10 Loss of G9a function does not grossly perturb T cell development.
Total thymocytes or splenocytes from the mice described in Figure 3.9 were stained as
indicated and analysed by FACS.

The earliest stages of thymic α:β T cell development are characterized by the lack of
expression of both the CD4 and CD8 co-receptors (double negative stage). Thymocytes
that successfully undergo recombination of the TCRβ chain expand rapidly and mature to
the CD4-CD8 double positive (DP) stage, during which TCRα recombination occurs.
The small percentage of DP cells which survive positive and negative selection silence
either CD4 or CD8 expression to become CD8 single positive (SP) or CD4 SP cells,
respectively. Although deletion of G9a in thymocytes with MX-cre was very efficient
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(Figure 3.8B), we saw no effect of G9a deficiency on T cell development by FACS
(Figure 3.10, left panels). Consistent with this finding and the inefficient deletion
observed in total splenocytes, the ratio of T cells (CD90+) to B cells (CD19+) in the
spleen was also unchanged (Figure 3.10, middle panels). However, the number of
immature B cells (IgM+IgDlo) in the periphery was reduced (Figure 3.10, right panels), as
would be expected on the basis of decreased IgM+ B cell production in the bone marrow.
Thus while G9a function is essential for B cell development, it is dispensable for T cell
development.

3.4 Analysis of G9a function in mature B cells
G9a and GLP were previously identified as components of a E2F6-containing
transcriptional repressor complex linked to maintenance of cells in the G0 (quiescent)
stage of the cell cycle (Ogawa et al., 2002). This stage corresponds to the resting state of
naive mature lymphocytes, thus raising the possibility that G9a and/or GLP might be
involved in maintenance of cell quiescence. It was therefore of significant interest to us
to investigate the effect of G9a deletion in peripheral lymphocytes. In order to begin to
address this issue, we first examined expression of G9a and GLP in resting and activated
peripheral B cells. Purified wild type splenic B cells were activated with either LPS
alone or LPS and Interleukin 4 (IL-4), and G9a and GLP expression were measured by
RT-PCR and Southern blotting as previously. Since triggering of naive B cells causes
dramatic upregulation of “housekeeping” genes such as HPRT, expression of IgM
germline transcripts was used as a loading control. As shown in Figure 3.11A, neither
G9a nor GLP was significantly upregulated in response to B cell activation.
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Figure 3.11 G9a/GLP expression during B cell activation and deletion of G9a
with CD19-cre. A. Purified wild type splenic B cells were activated with the
indicated stimuli and total RNA was collected on a timecourse. RT-PCR and
Southern blotting were performed as in Figure 3.2. B. Splenic B cells were
purified from G9afl/fl mice with or without the CD19-cre knock-in allele, and
lysates were immunoblotted with the indicated antibodies. The lower band in the
αG9a blot represents a cross-reacting cytoplasmic protein (discussed in Chapter
4).
Since G9a deletion in bone marrow causes a block in B cell development, it was
necessary to use a different driver strain in order to investigate possible functions of G9a
in mature B cells. As mentioned previously, deletion of Ezh2 in hematopoietic stem cells
with MX-cre also causes a severe block in B cell development at the pro-to-pre B cell
transition. However, deletion starting at the pro-B cell stage with the CD19-cre driver
allows production of peripheral B cells (Rickert et al., 1997; Su et al., 2003). We
therefore crossed G9afl/fl mice to the CD19-cre driver strain. G9a deletion in peripheral B
cells, as measured by Western blotting with a αG9a polyclonal rabbit antiserum produced
in the lab (described in Chapter 4), was complete (Figure 3.11B). As observed for Ezh2,
conditional deletion of G9a with the CD19-cre driver strain did not significantly perturb
B cell development in the bone marrow (Figure 3.12). Likewise, B cells were present in
spleen and the ratio of IgM+/IgD+ cells was unaltered (data not shown).
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Figure 3.12 Unaltered B cell development in G9afl/fl CD19-cre mice. Total bone
marrow cells from mice of the indicated genotypes were stained as in Figure 3.9 and
analysed by FACS.

In order to assess the contribution of G9a to maintenance of the G0 state, we examined
the response of wild type and G9a-deficient cells to mitogenic stimuli in vitro. Purified
splenic B cells loaded with the cell division tracker dye carboxyfluorescein succinimidyl
ester (CFSE) were stimulated with sub-optimal (1 µg/ml) or saturating (5 µg/ml)
concentrations of αIgM antibody or LPS in the presence or absence of IL-4. Cell
division is accompanied by linear dilution of the CFSE dye, allowing quantitation of cell
division by FACS.
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Figure 3.13 In vitro activation profile of G9a-deficient B cells. Purified splenic
B cells from G9afl/fl and G9afl/fl CD19-cre mice were labeled with CFSE and
activated with the indicated stimuli in vitro. Cells were analysed by FACS 72
hours after stimulation.
As shown in Figure 3.13, both wild type and G9a-deficient B cells proliferated
robustly in response to triggering by αIgM+IL-4, LPS ± IL-4, or LPS+αIgM. The only
difference in proliferation was seen under conditions of limited triggering with αIgM in
the absence of IL-4, in which samples a modest decrease in division of the mutant cells
could be measured. Importantly, no spontaneous division of G9a-deficient cells was
observed in the absence of stimulation, arguing against a fundamental role for G9a
activity in maintenance of quiescence.
52

Recently, it was reported that G9a physically interacts with the SET-domain
containing protein Blimp-1, a known “master regulator” of B cell differentiation into
plasma cells (Gyory et al., 2004; Shapiro-Shelef et al., 2003). Although Blimp has not
been shown to possess histone methyltransferase activity itself, it is thought to promote
plasma cell differentiation by inactivation of the B cell gene expression program through
interaction with multiple families of transcriptional repressors (Lin et al., 2003; Piskurich
et al., 2000; Shaffer et al., 2002; Yu et al., 2000). The interaction between G9a and
Blimp was shown to be essential for a separate Blimp-dependent activity, namely
repression of Interferon β (IFN-β) after induction in vitro. This raised the possibility that
G9a might contribute to Blimp-mediated plasma cell development as well.
We addressed this possibility by measuring induction of CD138/Syndecan-1
expression, an established plasmablast marker (Shapiro-Shelef et al., 2003), in the B cell
activation experiment described previously (Figure 3.13). Four days after stimulation,
strong plasmablast differentiation was seen in both wild type and mutant cells stimulated
with LPS only, and this was accompanied by extensive division of the cells as measured
by CFSE dilution (Figure 3.14). Similar results were obtained for wild type cells
stimulated with LPS+IL-4, but under this condition approximately half as many
plasmablasts were seen in the mutant sample. Stimulation of B cells with both LPS and
αIgM has been described to deliever an inhibitory signal which inhibits plasma cell
differentiation, even in the presence of strong division. This inhibitory effect was
maintained in mutant B cells (Figure 3.14), demonstrating that this effect in unlikely to be
mediated by induction of specific H3K9 dimethylation.
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Figure 3.14 Effect of G9a deficiency on plasma cell differentiation in vitro.
CFSE-labeled wild type or mutant B cells were activated in vitro with the indicated
stimuli and analysed by FACS 4 days after stimulation for plasmablast differentiation,
as measured by expression of CD138/Syndecan-1.

3.5 Summary
Overall, our studies of G9a conditional knockout mice indicate that G9a activity is
critically required for B cell development, but is not required for T cell development.
Within the B lineage, we find that G9a contributes to the pro-B to pre-B cell transition
during development, but is largely dispensable for activation and proliferation in the
periphery. We found no defect in upregulation of activation markers after stimulation in
vitro (data not shown), and cells proliferated at wild type levels in response to most
stimuli. In addition, plasmablast differentiation was completely unaffected in response to
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LPS, ruling out an essential role for G9a in Blimp-mediated repression in differentiating
B cells. Small differences were seen in the proliferative response of G9a-deficient B
cells to purely BCR-driven activation in the absence of IL-4, as well as in plasma cell
differentiation in response to LPS+IL-4. However, since the CD19-cre driver used in
these experiments is a knock-in into the CD19 locus, G9a-deficient cells are also
heterozygously deficient for the CD19 co-receptor. Complete loss of CD19 function is
known to cause defective T-cell dependent immune responses in vivo (Rickert et al.,
1995), and thus quantitatively different results on a heterozygous background must be
interpreted with caution.
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Chapter 4: Analysis of G9a methylation
4.1 G9a is lysine methylated in vitro and in vivo

Figure 4.1 G9a and GLP carry a conserved H3K9-like motif in their N terimini.
Protein sequences of G9a and GLP homologs from several species were aligned using
ClustalW software. Identical residues in at least four of six sequences are shown in red,
and the amino terminus of H3 is shown for comparison. The sequence listed
corresponds to residues 140-190 of human G9a. The positions marked “1” and “2”
above the sequences denote the two lysine residues conserved between human and
mouse G9a/GLP homologs. Abbreviations: h, human; m, mouse; x, Xenopus; d,
Drosophila.

While performing sequence alignments between the amino-termini of murine G9a and
GLP, we identified a stretch of eight amino acids which showed perfect identity between
the two (Figure 4.1). Extending the alignment to include human G9a and GLP, as well as
G9a homologs in Xenopus and Drosophila, we noted a high degree of conservation
within this motif, which contrasts with the relatively poor conservation of the
surrounding sequence. Most intriguing was the degree to which the core conserved motif
resembled the canonical H3K9 target sequence of G9a (Figure 4.1). This observation led
us to ask whether this H3-like sequence in G9a might be a target for lysine methylation.
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Figure 4.2 G9a K194 can be methylated in vitro. αFLAG immunoprecipitates
from 293 cells transiently transfected with the indicated constructs were used in an
in vitro HMTase assay against the peptide substrates listed. WT, unmodified
peptide; diMe, dimethyl K194 peptide; K-A, K165A mutant peptide; triMe,
trimethyl H3K9 peptide.

To address this possibility, we first assayed the ability of a peptide containing the
putative methylation site of human G9a (K165) to act as a substrate in an in vitro
methylation reaction. As a source of methyltransferase activity, we initially chose to use
human G9a itself, since this enzyme has been shown to possess high intrinsic HMTase
activity towards H3K9 (Tachibana et al., 2001). Methyltransferase assays using
immunoprecipitated FLAG-tagged hG9a demonstrated robust methylation of peptides
containing either the wild type H3K9 sequence or the wild type G9a K165 sequence
(Figure 4.2). Since the K165 peptide contains an additional conserved lysine, K169, we
also attempted to methylate a peptide containing the lysine of interest mutated to an
alanine (K165A). This mutant peptide failed to be methylated by hG9a in vitro,
demonstrating the specificity of the methylation reaction for the single lysine which most
closely resembles H3K9 (Figure 4.1). In addition, peptides carrying chemically
dimethylated K165 were completely refractive to further methylation (Figure 4.2), a
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finding consistent with previous reports demonstrating that G9a is specifically a di-, but
not tri-methylating enzyme (Peters et al., 2003).

Figure 4.3 Methylated G9a K194 peptide is recognized by a “multi-methyl”
lysine-specific antibody. The indicated peptides were probed by Western blot
with an antibody (α 4xdiMeK9) which recognized methyllysine in multiple
sequence contexts (see text). WT, unmodified peptide; diMe, dimethyl K194
peptide; K-A, K165A mutant peptide; triMe, trimethyl H3K9 peptide.

Having established that the H3K9-like K165 site in G9a can be methylated in vitro,
we next sought to determine whether this site is actually methylated in vivo. Studies of
histone methylation have been greatly aided by the production of antisera capable of
specifically recognizing modified residues. Of particular interest is an antiserum that was
raised against a branched-peptide antigen bearing the dimethyl H3K9 sequence
(α4xdiMeK9); this antibody has been shown to recognize various degrees of methylation
of H3K9, as well as lysine methylation of other sites in various histones, and has
therefore been termed a “multi-methyl” lysine specific antibody (Perez-Burgos et al.,
2004). We investigated whether this antibody might also react with methylated G9a K165
peptide. As shown in Figure 4.3, the α4xdiMeK9 antibody was able to recognize the
dimethylated but not unmethylated or alanine mutant K165 peptide by Western blot,
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demonstrating specific recognition of the methyl-modified form of G9a. We therefore
further used this antibody to determine whether G9a exists in a methylated state in vivo.

*

Figure 4.4 G9a exists in a methylated state in vivo. A. Schematic
representation of the region used to raise αG9a antibody. B. Western blot of
immunoprecipitations from nuclear or cytoplasmic 293 extracts using αG9a
antibody. Red asterisk marks the position of G9a; the strong signal below ~50
kD corresponds to cross reaction of the secondary antibody wih that used for
IP. C. Immunoprecipitation of endogenous hG9a from 293 cells, followed by
Western blot with αG9a or α4x(diMeK9) antibody as indicated.

In order to purify endogenous G9a, we raised an antiserum against an amino-terminal
fragment of murine G9a. The affinity-purified antibody recognizes both human and
mouse G9a in nuclear extracts, and immunoprecipitates H3K9- and G9a K165methylating activity (Figure 4.4A and B, and data not shown). Endogenous hG9a
immunoprecipitated from HEK293 nuclear extracts using αG9a antibody was probed by
Western blot with the α4xdiMeK9 antibody (Figure 4.4C). Reactivity with the multimethyl lysine antibody was readily observed, indicating that G9a is in fact methylated in
vivo.
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Figure 4.5 Identification of G9a methylation sites. A. Wild type or point mutant
G9a was immunoprecipiated from transiently transfected 293 cells and analysed by
Western blot with the indicated antibodies. Asterisk indicates cross-reaction with
light chain of the immunoprecipitating antibody. B. Immunoprecipitated FLAGhG9a was separated by SDS-PAGE followed by staining with Coomassie Blue. C.
Sites of methylation identified by mass spectrometry (indicated in red); both sites
were purely dimethylated. D. Alignment of MS1 and MS2 with H3K9 and H3K27.
Identical residues are shown in red, and conservative substitutions in yellow.
Abbreviations: EV, empty vector; WT, wild type FLAG-hG9a; K1, FLAG-hG9a
K165A; K1K2, FLAG-hG9a K94A K165A.

To determine the site of methylation recognized by the α4xdiMeK9 antibody, we
began by constructing point mutations of human G9a, mutating either one or both
conserved lysines in the originally-identified motif to alanine (Figure 1A, K165A or
K165,169A). To our surprise, mutation of a single lysine to alanine (K165A,
corresponding to the site of methylation in vitro) completely abolished recognition of
FLAG-hG9a by the α4xdiMeK9 antibody (Figure 4.5A).
In order to directly confirm the finding of G9a methylation on K165, we investigated
methylation of this site by mass- and tandem-mass spectrometry (MS and MS-MS).
Trypsin digests of immunoprecipitated FLAG-hG9a (Figure 4.5B) produced an MS peak
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consistent with the mass of a peptide (KTMSKPGNGQPPVPEK) bearing an oxidized
methionine and two methyl groups (Figure 4.5C). Further fragmentation of this peptide
and analysis by MS-MS yielded a spectrum consistent with the sequence of the predicted
peptide, including dimethylation of K165 (data not shown). Intriguingly, no peptides
bearing mono- or trimethylated lysines were observed, and unmethylated peptides were
similarly not detected, suggesting that the vast majority of the expressed G9a exists in the
dimethylated state. In addition to K165, we also identified an additional site of lysine
methylation, K94 (Figure 4.5C). Like K165, K94 was also dimethylated, and also existed
in a sequence context which closely resembled H3K9 (Figure 4.5D). For clarity, the
upstream K94 site is hereafter referred to as MS1 (Methylation Site 1) and the
downstream K165 site as MS2 (Methylation Site 2).
In order to further confirm our finding of endogenous G9a methylation, we raised an
antiserum against the dimethylated G9a MS2 peptide. Dot blot analysis of the affinitypurified antibody demonstrated strict requirement of methylation for recognition of the
immunizing peptide (Figure 4.6A). Surprisingly, peptides bearing dimethylation on MS2
as well as phosphorylation of the adjacent threonine were not recognized by this serum,
suggesting that recognition is specific for the methylated, non-phosphorylated version of
this site (data not shown). We further found that the immune, but not the preimmune
serum specifically recognized bands of the correct size for G9a in 293 nuclear extracts
(Figure 4.6B, indicated by red asterisk). Despite the sequence similarity between MS1
and MS2, it is clear that both the α4xdiMeK9 and αdiMeMS2 antisera specifically
recognize MS2 methylation, as MS1 point mutation had no effect on recognition by
antibody (Figure 4.6C). Since the MS2 site bears the strongest resemblance to H3K9 and
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is uniquely recognized by the α4xdiMeK9 antibody, we chose to further investigate the
biochemical consequences of methylation on this lysine.

Figure 4.6 Two different methyl-specific antibodies recognize methylation of G9a
MS2. A. Dot blot analysis using the indicated peptides and either the affinity purified
αG9a diMeMS2 antibody or pre-immune serum from the same rabbit. B. Western
blot analysis of cytoplasmic (Cy) or nuclear (Nu) 293 cells extracts, using the sera as
in (A). Red asterisk marks the position of endogenous G9a. C. Immunoprecipitates of
wild type or point mutant FLAG-hG9a probed with the indicated antibodies. Signal
from input samples probed with αFLAG antibody was visible on longer exposure
(data not shown).
4.2 G9a methylation controls interaction with HP1
Groundbreaking studies previously demonstrated that methylation of H3K9 is
sufficient to create a specific binding site for chromodomain-containing proteins of the
Heterochromatin Protein 1 (HP1) family (Lachner et al., 2001). Intriguingly, G9a has
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been shown to exist in a complex containing the predominantly euchromatic HP1
isoform, HP1γ, and to interact directly with HP1γ in vitro (Ogawa et al., 2002; Roopra et
al., 2004). These observations, together with the extensive sequence similarity between
MS2 and H3K9, as well as the finding that G9a exists in a methylated state in vivo, led us
to speculate that methylation of G9a on K165 could create a binding site for HP1γ. To
address this possibility, we asked whether interaction of G9a with HP1γ depended on the
presence of a methylatable lysine at the MS2 site. Wild type or MS2 KA point mutant
hG9a were expressed in 293 cells, and assayed for their ability to associate with HP1γ. As
shown in Figure 2D, wild type G9a was able to co-immunoprecipitate HP1γ, whereas the
MS2 K165A mutation completely eliminated this interaction, despite the presence of an
unmutated MS1 site. By contrast, the previously reported interaction between G9a and
GLP was not affected by the MS2 KA mutation (data not shown).

*
Figure 4.7 Interaction of G9a with HP1γ requires an intact MS2 methylation
site. Immunoprecipitates of transiently transfected wild type (WT) or K165A (KA)
FLAG-hG9a were analysed by Western blot for co-immunoprecipitation of
endogenous HP1γ. Asterisk indicates cross-reaction with the heavy chain of the
immunoprecipitating antibody.
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These results suggest, but do not directly prove that interaction of HP1γ with G9a
depends on methylation of MS2. We therefore examined whether the presence of methyl
groups per se was required for HP1 binding. MS2 peptide matrices containing either
unmodified lysine, dimethylated lysine or a lysine to alanine mutation were incubated
with unmanipulated nuclear extracts in order to determine whether HP1γ could directly
interact with the methylated peptide. We found that recovery of HP1γ as well as HP1α
on the beads was significantly enhanced by pre-existing methylation of the MS2 peptide,
and was completely blocked by mutation of the methylated lysine to alanine (Figure 4.8).
In contrast, the nuclear protein Lamin B was not recovered with any peptide.

Figure 4.8 Methylation of MS2 strongly promotes binding of HP1 isoforms. The
indicated peptides were covalently coupled to beads and incubated in unmanipulated
293 extracts. After thorough washing, associated proteins were examined by Western
blot. WT, unmodified peptide; diMe, dimethyl MS2; KA, MS2 K165A peptide.

The interaction of HP1 isoforms with unmethylated peptide, while substantially less
efficient than in the presence of methylation, was still detectable. This could represent
either low-affinity interaction between HP1 and unmethylated lysine, or de novo
methylation of the MS2 peptide by methyltransferases present in the extract. These
possibilities can be distinguished through the use of in vitro translated HP1 protein, as
contaminating HMTases should be less abundant or absent in the reticulocyte lysates
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used for translation. We therefore incubated wild type, dimethylated or point mutant
MS2 peptides with in vitro-translated HP1 proteins, followed by SDS-PAGE and
autoradiography (Figure 4.9). Only the methylated MS2 peptide was able to interact with
HP1 under these conditions, demonstrating that the interaction of methylated G9a with
HP1 requires lysine methylation.

Figure 4.9 Methylation of G9a MS2 is required for HP1 binding. Beads
conjugated with the indicated peptides were incubated with in vitro-translated HP1
isoforms, and binding assessed by SDS-PAGE and autoradiography.

4.3 Studies of G9a methylation in vivo
Further investigation of the mechanism and possible consequences of G9a methylation
required a cell system lacking endogenous G9a expression. To create such a system, we
utilized the conditional G9a mouse mutant described earlier (Chapter 3). Since G9adeficient Mouse Embryonic Fibroblasts (MEFs) fail to proliferate in culture (Tachibana
et al., 2002), we chose to use a multistep strategy to derive deficient MEFs. First,
immortalized G9afl/fl (“floxed”) cell lines would be derived by infection of primary MEFs
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with a retrovirus expressing SV40 large-T antigen. These would be subsequently
infected in bulk with a Cre-expressing adenovirus to produce G9a deficiency (G9aΔ/Δ),
and subcloned by limiting dilution to produce clonal populations. Finally, the subcloned
cells would be infected with retroviruses carrying either an empty vector (KO), wild type
FLAG-hG9a (WT), MS2 K165A FLAG-hG9a (KA) or FLAG-hG9a carrying a single
amino acid point mutation in a residue known to be critical for enzymatic activity in other
SET-domain contain HMTases (H1093K, abbreviated HK). The overall strategy is
summarized in Figure 4.10.

Figure 4.10 Scheme for creation of G9a-deficient reconstituted MEFs.
Abbreviations: RV, retrovirus; TAg, SV40 Large T antigen.

To examine the efficiency of adenoviral Cre expression, we first performed a
timecourse of Adeno-Cre deletion in primary MEFs. Two independent G9afl/+ or G9afl/fl
embryos were used to establish primary cultures, which were infected at high multiplicity
of infection with Adeno-Cre. Samples were taken at 24 hour interval, and deletion was
monitored by Western blot with αG9a antibody. As shown in Figure 4.11, complete
deletion at the protein level was seen within 24 hours. Interestingly, a band crossreacting with the αG9a antibody was seen to increase in expression level in parallel with
G9a deletion.
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Figure 4.11 Deletion of G9a in vitro with Adeno-Cre. Independent primary
MEF littermate cultures of the indicated genotypes were infected with Creexpressing adenovirus and followed by Western blot to monitor deletion.

The presence of a cross-reacting band which increased upon G9a deletion raised the
possibility that G9a deletion might actually produce an in-frame splice product. To
understand the properties of this cross-reacting band further, we immunoprecipitated G9a
from floxed cells using our αG9a antibody either with or without deletion using Adenocre treatment, and then performed Western blot with the same antibody (Figure 4.12A).
Surprisingly, the cross-reacting band was immunoprecipitated even in deleted cells, while
co-IP of endogenous GLP (examined using our own αGLP antibody) was abolished. We
sought to further understand the nature of the cross-reacting protein by performing
nuclear fractionation (Figure 4.12B). This demonstrated that the cross-reacting protein is
purely cytoplasmic, and thus most likely not significant for our experiments relating to
nuclear functions of G9a and G9a methylation, although this observation may be very
significant in other contexts (discussed below).
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Figure 4.12 G9a deletion with Adeno-cre disrupts interaction with GLP and does
not produce a nuclear truncation product. Primary MEF cultures were mockinfected or infected with Adeno-cre. A. Whole cell extracts were immunoprecipitated
with αG9a antibody and examined for co-IP of GLP by Western blot. B. Nuclear and
cytoplasmic fractions were prepared to examine the distribution of the cross-reacting
band seen with αG9a antibody.

Deleted immortalized cells were subcloned to produce homogeneous populations, and
then reconstituted with retrovirus as indicated in Figure 4.10. Genotyping of the
retrovirally infected cell lines by PCR demonstrated that all lines remained completely
deleted for G9a at the genomic DNA level after extensive passage in culture (Figure
4.11A). Western blot analysis of nuclear lysates from the reconstituted cell lines
demonstrated the expected overexpression of G9a in the retrovirally transduced cell lines
(Figure 4.11B). Complete loss of G9a expression has been shown to result in a severe
decrease in euchromatic H3K9 dimethylation, with partial relocalization of the dimethyl
H3K9 mark to pericentric heterochromatin (Peters et al., 2003; Rice et al., 2003).
Consistent with these observations, both fully mutant MEFs and those reconstituted with
catalytically inactive G9a showed a dramatic reduction in the overall level of H3K9
dimethylation, as detected by immunoblotting with a modification-specific antibody
(Figure 3B). In contrast, the overall levels of HP1γ remained unchanged (Figure 3B).
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Figure 4.13 Analysis of reconstitution in G9aΔ/Δ MEFs. A. G9a genotyping PCR
on genomic DNA from undeleted G9afl/fl MEFs (-Ad) or two independent subclones of
G9aΔ/Δ MEFs (+Ad) reconstituted with empty retrovirus (EV), wild type (WT), MS2
KA (KA) or catalytically inactive (HK) FLAG-hG9a. Expected product sizes: floxed,
371 bp; deleted, 574 bp. B. Reconstituted lines from clone #3 were analysed by
Western blot with the indicated antibodies.
In order to determine whether the euchromatic distribution of HP1γ was altered in the
presence of the MS2 point mutation, we performed indirect immunofluorescence (IF)
using either HP1γ, G9a or diMeH3K9-specific antibodies. G9a-deficient cells showed
the expected loss of euchromatic diMeH3K9, with weak accumulation of dimethyl H3K9
at pericentric heterochromatin (Figure 4.12 and data not shown). G9a deficiency also
induced increased localisation of HP1γ to pericentric heterochromatin, which, given the
unchanged overall levels of HP1γ, implies impaired euchromatic localisation.
Reconstitution of deficient cells with wild type G9a completely rescued the effects on
both diMeH3K9 and HP1γ distribution (Figure 4.12).
Cells lacking endogenous G9a and expressing only the non-methylatable point mutant
showed an HP1γ localisation pattern that was grossly identical to cells expressing wild
type G9a, indicating that methylation of G9a is not required for bulk euchromatic
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localisation of HP1γ. Likewise, both G9a and diMeH3K9 were distributed as in wild
type cells, indicating that MS2 methylation is dispensable for G9a localization and
histone methylation activity. Interestingly, cells reconstituted with catalytically inactive
G9a continued to demonstrate mislocalisation of HP1γ, suggesting that, as with targeting
of HP1α to pericentric heterochromatin (Lachner et al., 2001), proper euchromatic
targeting of HP1γ depends mainly on histone methylation per se (Figure 3C).

Figure 4.14 G9a methylation on MS2 is not necessary for bulk G9a, HP1γ or
diMeH3K9 localization in vivo. MEF lines of the indicated genotypes were
examined by indirect immunofluorescence using the listed antibodies and
couterstained with DAPI. Only the specific stain is shown (DAPI channel excluded).
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The creation of cell lines which do not express endogenous G9a further allowed us to
address the question of which HMTase is responsible for G9a methylation on MS2.
Initial experiments indicated that while G9a can robustly methylate G9a peptides in vitro,
the related H3K9 methyltransferase Suv39H1 cannot (data not shown). This finding is
consistent with the observation that G9a catalytic activity is ~20-fold higher than that of
Suv39H1, most likely due to a histidine to arginine substitution within the G9a SET
domain which hyperactivates the enzyme (Tachibana et al., 2001). However, the two
non-histone targets of lysine methylation reported to date, TAF10 (Kouskouti et al.,
2004) and p53 (Chuikov et al., 2004), were both shown to be targets of the SET9
methyltransferase, which has not yet been demonstrated to possess any in vivo HMTase
function, thus raising the possibility that the enzymes targeting histones and non-histone
proteins may be mutually exclusive.
We first chose to test whether G9a might be responsible for its own methylation.
FLAG-hG9a was immunoprecipitated from reconstituted MEF clones expressing either
G9a WT, MS2 K165A or the H1093K catalytic mutant, followed by immunoblotting
with the α4xdiMeK9 antibody, which uniquely recognizes MS2 methylation. Whereas
wild type G9a was readily recognized by this antibody, both the MS2 and catalytic point
mutants were not (Figure 4.13). The lack of G9a methylation in the presence of a
catalytic point mutation demonstrates that G9a is required for its own methylation.
Whether this methylation occurs in cis or in trans remains an outstanding question.
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Figure 4.15 Methylation on MS2 requires G9a catalytic activity. Wild type
(WT), MS2 KA (KA) or catalytically inactive (HK) G9a was immunoprecipiated
from reconstituted G9a-deficient MEFs and examined by Westwen blot with the
indicated antibodies.
The presence of a methylatable target site within the G9a methyltransferase clearly
raised the possibility that this site could behave in a manner similar to that seen in
kinases, where pseudo-substrate sites located in cis are able to modulate kinase activity
(Kemp et al., 1994). Since G9a is known to homodimerize (Tachibana et al., 2005), we
therefore took advantage of the reconstituted MEFs to measure the catalytic activity of
MS2 KA mutant G9a in a background devoid of endogenous G9a methyltransferase
activity. FLAG-tagged wild type or MS2 KA G9a were immunoprecipitated from MEFs
and assayed in vitro for methyltransferase (MTase) activity against either H3 or G9a MS2
peptides. Equal amounts of G9a were recovered from all cell lines, and MTase activity
of wild type and MS2 KA G9a were equal on both substrates (Supp. Figure 4). Since
MS2 KA G9a retains its ability to heterodimerize with endogenous wild type GLP, it was
possible that the activity measured with the methylation site point mutation was due to
co-IP of GLP. We therefore also assayed the MTase activity of the G9a H1093K
catalytic dead mutant, which is unable to reconstitute G9a activity in vivo but still
interacts with GLP (Figure 3B, C, and data not shown). This mutant still exhibited an
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~65% reduction in catalytic activity in vitro, demonstrating that the activity measured for
the MS2 point mutation is not simply due to interaction with GLP (Supp. Figure 4).

Figure 4.16 G9a MS2 methylation is not required for catalytic activity. Wild type
(WT), MS2 KA (KA) or catalytically inactive (HK) FLAG-hG9a were
immunoprecipitated from reconstituted MEF cell lines. A. Western blot analysis of
G9a recovery from each cell line. B. HMTase assay on unmodified H3(1-20) or G9a
MS2 peptide using immunoprecipitated protein from (A). C. Quantitation of the
results shown in (B).
4.4 Potential control of HP1 binding by phosphorylation
A major issue in the study of lysine methylation has been the possibility of reversal of
this mark. Significant progress has been made recently through identification of an
enzymatic activity capable of active demethylation of lysines 4 and 9 in H3 (Lee et al.,
2005b; Metzger et al., 2005; Shi et al., 2004). It has also been proposed that ejection of
HP1 bound to methyllysine could be achieved through phosphorylation of serine residues
found adjacent to H3K9 and H3K27 (Fischle et al., 2003a). Such “methyl-phos
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switches” have been proposed to comprise a reversible mechanism for localized
regulation of HP1 binding to histones. The presence of phosphorylatable residues (serine
and threonine, respectively) at the positions corresponding to H3 serine 10 in the MS1
and MS2 sites (Figure 4.15A) raised the possibility that phosphorylation at these sites
could have a similar regulatory effect on HP1 binding to G9a.
To investigate this possibility, we first sought to determine whether the threonine at
position 166 in MS2 could be phosphorylated by the dominant mitotic H3S10 kinase,
Aurora B (Hsu et al., 2000). As a source of endogenous Aurora B, we used extracts
prepared from unfertilized Xenopus oocytes, which are naturally arrested at meiotic
metaphase II and contain high Aurora B kinase activity (Bolton et al., 2002; Murray,
1991). The Aurora B-containing Chromosomal Passenger Complex (CPC) was
immunoprecipitated from Xenopus egg extracts using an antibody directed against the
CPC member Incenp (Sampath et al., 2004), and the immunoprecipitated material was
used in an in vitro kinase assay on various peptide substrates. As shown in Figure 4.15B,
the Aurora B complex readily phosphorylated a peptide containing the H3K9 sequence.
This phosphorylation was completely blocked by mutation of serine 10 to alanine,
consistent with the known specificity of Aurora B (Bolton et al., 2002; Crosio et al.,
2002; Giet and Glover, 2001). A G9a peptide containing the MS2 methylation site was
also robustly phosphorylated, and this phosphorylation was unaffected by the presence of
dimethylation on MS2. Since the MS2 peptide contains multiple phosphorylatable
residues, we also produced a peptide carrying both MS2 dimethylation as well as
phosphorylation on T166; this peptide was completely resistant to further
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phosphorylation, demonstrating that phosphorylation by Aurora B is specific for T166,
the single residue in the MS2 peptide which aligns with H3 serine 10.

Figure 4.17 G9a MS2 peptide can be phosphorylated by Aurora B in vitro. A.
Alignment G9a/GLP MS2 sites with H3K9 and H3K27 demonstrates conservation
of a phosphorylatable residue (shown in yellow) adjacent to the methylation site
(shown in red). B. The Aurora B-containing Xenopus chromosomal passenger
complex (CPC) was immunoprecipitated and used in an in vitro kinase assay with
the indicated peptides as substrates. Coomassie staining of the same gel is shown
below. The labeled high molecular weight species correspond to known Aurora B
targets within the CPC. WT, unmodified peptide; S10A, H3 Ser10Ala mutant
peptide; diMe, dimethyl MS2 peptide; MePh, dimethyl MS2 T166 phosphorylated
double-modified peptide.
We next investigated whether phosphorylation of T166 could modulate HP1 binding
to G9a in vitro. Bead matrices coupled with either no peptide, wild type, dimethyl or
dimethyl-phospho G9a MS2 peptide were incubated with in vitro-translated HP1γ as
previously. As expected, neither the empty beads nor the unmodified peptides bound
significant amounts of HP1γ, while the dimethyl MS2 beads bound HP1γ strongly
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(Figure 4.16A). Significantly, this binding was completely eliminated by the presence of
phosphorylation on the adjacent threonine (T166). The lack of HP1γ binding to the
dimethyl-phospho beads was not due to reduced coupling efficiency of the peptide, since
binding could be quantitatively restored by pre-treatment of the phosphorylated peptide
matrix with Protein Phosphatase 1 (PP1; Figure 4.16A, quantitation shown in 4.16B).
These results demonstrate that, as with H3, phosphorylation adjacent to a site of
methylation in G9a has the potential to reverse the biochemical readout of this mark.
Thus the “tail” of G9a mimics the biochemical properties of the H3 tail itself in the
following ways: the G9a amino terminus is multiply methylated; this methylation is at
least in part carried out by an H3K9-specific methyltransferase; methylation creates a
binding site for HP1; a G9a tail peptide can be phosphorylated by a mitotic kinase; and
finally, methyl-dependent HP1 binding is blocked by adjacent phosphorylation.

Figure 4.18 Phosphorylation of T166 blocks binding of HP1γ to methylated MS2.
A. Beads conjugated with the indicated peptides were incubated with in vitro
translated 35S-labeled HP1γ or Pax5, and binding examined by SDS-PAGE and
autoradiography. The dimethyl-phospho MS2 peptides were also pre-treated with
Protein Phosphatase 1 (PP1) to control for peptide coupling efficiency. Abbreviations:
Pre, pre-pull down sample; Sup, post-pull down supernatant; PD, bead fraction after
pull down. B. Quantitation of the results in (A).
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CHAPTER 5: DISCUSSION
5.1 Studying histone modification in the immune system
The study of chromatin structure and function has been challenging for many of the
same reasons that make the subject compelling: the extreme conservation of histones and
the proteins that bind and modify them make genetic approaches in higher eukaryotes
difficult. It is therefore not surprising that significant insights into the physiological
functions of histone modification in vertebrates have been made through studies of the
immune system, where loss of function phenotypes do not necessarily cause lethality
(Corcoran et al., 1998; Johnson et al., 2004; Su et al., 2003; Su et al., 2005).
Within the immune system, the processes that have been examined the most
intensively from a chromatin perspective have unsurprisingly been those involving DNA
recombination reactions: V(D)J recombination and class switch recombination (CSR).
While the potential contribution of chromatin-based mechanisms for control of CSR are
only beginning to be addressed (see Chapter 1), “locus accessibility” has been an issue at
the forefront of studies on V(D)J recombination for quite some time (Corcoran et al.,
1998; McMurry and Krangel, 2000; Sleckman et al., 1996). V(D)J recombination in B
cells poses a particular challenge, as the immunoglobulin heavy chain locus spans several
megabases, and must be activated in a stepwise manner for recombination in a process
that may require physical contraction of the locus (Chowdhury and Sen, 2001; Fuxa et
al., 2004).
Intriguingly, many of the molecules and pathways demonstrated by knockout studies
to be important for immunoglobulin V(D)J recombination demonstrate similar loss of
function phenotypes: disruption of the IL-7 receptor α chain, the transcription factor Pax5
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or the histone methyltransferase Ezh2 all cause a block in pro- to pre-B cell development,
with progressively less efficient use of variable genes located at a distance from the D
and J loci (Corcoran et al., 1998; Hesslein et al., 2003; Su et al., 2002). However, an
important point to consider in analysing the results of such gene targeting studies is that
the marked similarity in phenotype may reflect either a common function for these
disparate molecules, or a non-specific effect of perturbing lymphocyte development.
The possibility that failure of B cell development might reflect a more general cell
biological problem is significant, since many genes whose deletion has a phenotype in
lymphocyte development demonstrate developmental failure at precisely the stages
during which cells undergo their most dramatic bursts of cell division (Chi et al., 2003;
Cobb et al., 2005; Corcoran et al., 1998; Muljo et al., 2005; Su et al., 2002). It is
therefore plausible that deletion of crucial chromatin regulators with cell-type
independent functions causes a non-specific stress leading to developmental arrest. This
would imply that many of the “specific” phenotypes generated in developing
lymphocytes are specific mainly due to the experimental system used. This issue is of
particular concern in the setting of conditional mutagenesis, which by its nature produces
an artifactual degree of specificity.
However the argument in favor of a specific effect is supported by many lines of
evidence, including the fact that while the overall effect of these knockouts may be
similar, there are many specific differences as well. For instance, while loss of either
Pax5 or IL-7Rα blocks development at the pro-B stage with reduced usage of 5’ V genes,
Pax5 deficiency is not associated with a lack of accessibility of these gene segments (as
measured by histone acetylation and germline transcription), while IL-7Rα deficiency is
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(Corcoran et al., 1996; Hesslein et al., 2003). Similarly, while the pro-B cell block in
Ezh2 deficiency can be rescued by providing a pre-rearranged Ig heavy chain, Pax5
deficiency cannot (Su et al., 2002; Thevenin et al., 1998), arguing for a specific function
for Ezh2 in V(D)J recombination per sé.
Also arguing for the specificity of these developmental blocks are the observations
that some proteins, such as Ezh2 and G9a, appear critical for B cell development, but
largely dispensable for activation and proliferation of peripheral B cells (Figure 3.13 and
3.14;(Su et al., 2002). Similarly, while G9a deletion severely blocks B cell development,
its loss appears to have no obvious effect on α:β T cell development, which is also
accompanied by rapid cell division during the double negative to double positive
transition (Figure 3.10). These instances of undisturbed cell division in the absence of
proteins such as G9a and Ezh2 lend credence to the suggestion that the observed
developmental phenotypes are specific. However, it is difficult to overcome the formal
argument that developing B cells are intrinsically more sensitive to the overall “health” of
the cell, and therefore more non-specifically sensitive to manipulation. It will therefore
be necessary to continue to interpret developmental phenotypes with caution.

5.2 Possible functions for G9a and GLP in developing lymphocytes
Our studies and those of other groups have shown that G9a and GLP are essential for
the vast majority of euchromatic H3K9 dimethylation (Tachibana et al., 2002; Tachibana
et al., 2005). Several groups have attempted to address the possible roles of euchromatic
H3K9 methylation in the control of V(D)J recombination in T and B cells. This has
mainly taken the form of chromatin immunoprecipitation (ChIP) analysis of the Ig and
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TCR loci with modification-specific antibodies (Johnson et al., 2004; Morshead et al.,
2003), which collectively suggested that diMeH3K9 might be enriched on inactive gene
segments. This hypothesis was strengthened by the finding that direct recruitment of the
G9a SET domain to the VEGF promoter was sufficient to initiate silencing (Snowden et
al., 2002), and that artifically “tethering” a catalytic fragment of G9a to a TCR locus
minigene was sufficient to inhibit germline transcription and subsequent V(D)J
recombination (Osipovich et al., 2004). Such experiments imply that localized
recruitment of G9a and/or GLP could represent a powerful mechanism for diminishing
locus accessibility. However, such experiments are limited by their artificiality and
inability to distinguish between simple correlation and a more causal role for diMeH3K9
in gene silencing.
The main alternate hypothesis, that localized histone methylation might “mark” target
loci for recombination, has to date not been addressed in the immune system. However,
there is a precedent for such a marking system in the unicellular eukaryote Tetrahymena,
where localized domains of H3K9 methylation may function to tag sites of recombination
during macronuclear development (Taverna et al., 2002). The unimpaired germline
trancription observed in Ezh2-deficient B cells is also compatible with a model in which
histone methylation either directly or indirectly targets recombination activity to
particular variable region genes. If this were indeed the case, it is possible that such an
effect might be overridden in the “tethering” experiments discussed earlier by the use of
truncated G9a, which is unlikely to partner correctly with its endogenous binding
proteins [Figures 4.7 and 4.12; (Osipovich et al., 2004; Roopra et al., 2004)].
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The results reported here may allow discrimination between these two models for the
function of histone methyltransferases in lymphocyte development since, in contrast to
Ezh2, we only observe defective development of B cells in the absence of G9a (Figure
3.9 and 3.10; (Su et al., 2005). The grossly normal development of G9a-deficient T cells
would seem to exclude a non-redundant role for H3K9 dimethylation in “marking” of VH
genes for recombination, although cell-type specific effects cannot be excluded. Overall,
the existing data on G9a are most consistent with a role for diMeH3K9 in promoting
immunoglobulin heavy chain recombination specifically, possibly through
heterochromatin-induced contraction of the Ig locus.
While our data do not directly address whether G9a-mediated methylation might also
restrict recombination to particular TCR loci as proposed previously (Osipovich et al.,
2004), this question is addressable using the genetic systems reported here. One
prediction of models in which diMeH3K9 limits recombination is that loss of this mark
should allow promiscuous recombination. It will therefore be of interest to determine
whether disruption of G9a expression allows, for instance, productive TCRα/β
recombination in non-T cells, or co-expression of κ and λ light chains in individual B
cells. Similarly, a classical experiment in molecular immunology was the demonstration
that RAG-1 and RAG-2 were capable of potently inducing V(D)J recombination when
co-transfected into NIH-3T3 cells (Oettinger et al., 1990; Schatz et al., 1989). It would
be interesting to repeat such an experiment in G9a-deficient fibroblasts, which would be
expected to undergo recombination at a much higher rate if diMeH3K9 functioned
endogenously to decrease recombinase access to its substrates.
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5.3 G9a methylation as an extension of the histone code
Over four decades ago, Allfrey, Mirsky and colleagues made the initial observation
that histones could exist in a lysine methylated state in vivo (Allfrey et al., 1964). The
first evidence for protein lysine methylation, however, came from studies a decade earlier
of a non-histone target, the flagellar protein of Salmonella (Ambler and Rees, 1959). A
possible connection between histone and non-histone methylation systems was proposed
by Jenuwein and colleagues in their description of the first cloned histone
methyltransferase, Suv39H1, where it was speculated that the same HMTases that
modified histones might also act as more general “MTases” on non-histone targets (Rea
et al., 2000). Credibility was lent to this hypothesis by the recent description in yeast of
Set1-mediated methylation of a kinetochore component, Dam1 (Zhang et al., 2005).
However, as with the previously described targets TAF10 and p53, lysine methylation of
Dam1 was observed on a site lacking similarity to histones, leaving possible functional
similarities between histone and non-histone methylation obscure (Chuikov et al., 2004;
Kouskouti et al., 2004; Zhang et al., 2005). Thus the possibility that “modification
cassettes” might exist in non-histone proteins has until now rested on the basis of
sequence similarity alone (Fischle et al., 2003a).
The results reported here on G9a methylation directly demonstrate that the
modification systems operating on histones are indeed conserved to non-histone proteins,
and therefore likely represent a universal feature of protein regulation in eukaryotes. We
find that highly conserved histone-like sequence motifs, which we term histone mimics,
exist in the amino-terminal “tail” of the histone methyltransferase G9a, and that at least
one of these motifs behaves in a manner almost identical to H3K9 with respect to
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methylation, binding of methyllysine by HP1, and the ability of this interaction to be
relieved by phosphorylation of an adjacent residue (Figures 4.4, 4.7, 4.15 and 4.16).

Figure 5.1 Alignments of G9a MS1 and MS2 A. Alignment of MS1 from
various species with H3K4. B. Alignment of MS2 with H3K9. Residues identical
in G9a homologs (A) or between G9a and GLP (B) are indicated in red;
conservative substitutions are indicated in yellow. Abbreviations: Mm, Mus
musculus; Hs, Homo sapiens; Rn, Rattus norvegicus; Xl, Xenopus laevis.

While our studies to date have been confined to the MS2 methylation site, it is clear
that an important area of investigation for the future will be to define the degree to which
the MS1 site behaves analogously to MS2 and H3K9. Recently the S. cerevisiae
chromodomain-containing protein Chd1 and the mammalian WD40-repeat protein
WDR5 were described to specifically interact with methylated H3K4 (Pray-Grant et al.,
2005; Wysocka et al., 2005). The MS1 site demonstrates little sequence similarity to
H3K4 (Figure 5.1A), but also differs from H3K9 and MS2 in that MS1 does not contain a
consensus Aurora phosphorylation site [R/K-X-S/T, Figure 5.1A; (Ohi et al., 2004)].
This raises the possibility that, similar to H3K4, lysine methylation of MS1 may define
interaction with a distinct class of effector modules.
In addition to the potential interaction of unique binding proteins with methylated
MS1, the scope for combinatorial modification of G9a may also be significantly extended
by additional modifications. For instance, we note that the MS2 site contains a lysine
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(K169) that is conserved between G9a and GLP homologs in human and mouse, and
which aligns within one amino acid of H3K14, a major site of histone acetylation in H3
[Figure 5.1b; (Strahl and Allis, 2000)]. We believe that G9a K169 will also prove to
exist in an acetylated state in vivo, and indeed that the entire range of post-translational
modifications on histones may also be present on G9a.
The complexity of G9a modification may itself represent only one mode of regulation
of G9a activity. We have consistently observed that our G9a antibody cross-reacts with a
cytoplasmic band of ~120 kD (Figure 4.4). This band is reproducibly induced by stimuli
which cause cell stress, including adenoviral infection and freeze-thawing (Figure 4.11
and data not shown). Importantly, deletion of G9a with CD19-cre, which should not
induce a stress response, causes a dramatic reduction in the amount of this cytoplasmic
cross-reacting band, implying that it is produced from the G9a locus (Figure 3.11B). We
believe that this band may therefore represent a stress-inducible cytoplasmic G9a splice
variant. This possibility is supported by the fact that the G9a genomic locus is contained
within the MHC class III region, which is known to encode many proteins upregulated in
response to stress and immune activation (Brown et al., 2001; Hauptmann and Bahram,
2004; Spike and Lamont, 1995). The recent finding that the predominantly nuclear
histone methyltransferase Ezh2 may have unexpected cytoplasmic functions (Su et al.,
2005) suggests that cytoplasmic G9a might have important roles in the cellular response
to “innate” activation.
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5.4 Possible functions of G9a methylation
What are the physiological corollaries of G9a automethylation and HP1 binding? One
obvious possibility is that methylation of G9a regulates its ability to control transcription.
However, we did not detect any significant difference in steady-state transcriptional
activity by microarray analysis of G9a-deficient MEFs reconstituted with either wild type
or MS2 point mutant G9a (data not shown). This may reflect inherent redundancy in this
system, since the related protein GLP carries an identical set of methylation sites, and has
been described to heterodimerize with G9a [Figure 4.1; (Tachibana et al., 2005)]. We
find this explanation unsatisfactory however, given that HP1γ was not recovered
following immunoprecipitation of G9aMS2KA, despite the presence of co-precipitated GLP
(Figures 4.7, 4.12 and data not shown). Alternatively, although methylation of MS2
uniquely defines the interaction between G9a and HP1γ, it is possible that the MS1 site is
physiologically redundant to MS2 in vivo. However the evolutionary conservation of
both sites would not be expected if they were in fact redundant to one another.
Rather, we believe that our findings reflect the inherent plasticity of chromatin
modification systems, where several activities are typically brought to bear
simultaneously to regulate gene expression. For example, G9a has been found to exist in
large repressor complexes containing HMTases (G9a and GLP), repressive transcription
factors (CtBP, E2F6 and CDP/cut), histone deacteylases (HDACs 1 and 2) and an H3K4
demethylase (LSD1/NPAO), the activity of each of which is capable of transcriptional
repression (Lee et al., 2005b; Nishio and Walsh, 2004; Oberley et al., 2003; Ogawa et al.,
2002; Shi et al., 2004; Shi et al., 2003; Trimarchi et al., 2001). Indeed, it has been
reported that H3K9-methylation by the G9a SET domain alone is sufficient to induce
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HDAC-dependent gene silencing in the absence of HP1 recruitment (Stewart et al.,
2005). These findings are consistent with our observation that reintroduction of the
catalytically inactive G9aH1093K allele into G9aΔ/Δ cells itself only deregulates the
transcription of a relatively small number of genes (data not shown), despite the neartotal absence of euchromatic H3K9 dimethylation (Fig. 3C). This may reflect a relative
stability of the existing transcriptional program in these cells, which might be maintained
through mechanisms requiring neither histone nor G9a methylation (e.g. histone
deacetylation and demethylation).
A clearer assessment of the role of G9a methylation in G9a-mediated repression will
ultimately require the analysis of animals harbouring both conditional deletions and
single and compound knock-in alleles at the methylation sites of interest. Such tools will
allow the analysis of methylation function at endogenous expression levels, and in a
developmental context in which gene expression must be dynamically controlled in order
to establish and perpetuate transcriptional memory (Peters and Schubeler, 2005).
Considering the impossibility of performing genetics in mammals on the multicopy
histone genes, as well as the potential for histone-like complexity of G9a modification, it
is possible that the G9a conditional knockout model will also provide the first genetic
platform in mammals for studying key predictions of the histode code hypothesis.

5.5 Potential histone mimics in chromatin-associated proteins
In addition to their relevance for our understanding of G9a function, the present
studies strongly suggest that histone mimicry is a widespread and conserved
phenomenon. An informative example of this conservation is seen in the G9a homologue
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of Drosophila (dG9a, Figure 4.1); dG9a clearly contains a potential methylation site, but
this exists in a simplified sequence context lacking both an upstream (MS1-type)
methylation site and an adjacent phosphorylatable residue. One intriguing possibility is
that the H3K9 mimic in dG9a represents an ancestral methylation site, which has
subsequently been expanded and elaborated upon in vertebrate G9a homologues. Such a
scenario is reminiscent of the C-terminal domain (CTD) of the RNA polymerase II RPB1
subunit, in which the number of heptapeptide repeats has increased through evolutionary
time (26 repeats in yeast, 44 in Drosophila and 52 in humans), in step with increasing
developmental and organismal complexity (Meinhart et al., 2005; Stiller and Hall, 2002).

Figure 5.2 Potential H3K9 histone mimics in chromatin-associated
proteins. H3K9-like sites are highlighted in red, and potential H3S10-like
sites in yellow. Abbreviations: FACT, facilitates chromatin transcription;
RPA194, RNA Polymerase I 194 kD subunit; PBCV, Paramecium bursaria
chlorella virus.
In contrast to the simplified methylation site of dG9a, we find complete potential
H3K9-type methylation/phosphorylation mimics in many vertebrate proteins involved in
transcription and chromatin regulation. These include the heterochromatic histone
variant macroH2A1, the H2A/H2B-interacting histone chaperone FACT (Facilitates
Chromatin Transcription) and the RNA polymerase I subunit RPA194 (Figure 5.2). The
occurence of H3 mimics in so many proteins involved in transcriptional regulation

87

suggests a basic role in the coordination of transcription with histone dynamics (e.g.
modification, deposition and/or removal). This again raises an analogy with the RNA Pol
II CTD, which is known to function in coordination of transcription with cotranscriptional events such as capping, splicing and polyadenylation (Proudfoot et al.,
2002). Indeed, it was recently demonstrated that both diMeH3K9 and HP1γ are present
specifically in the coding regions of actively transcribed genes, and that their presence
requires Pol II-mediated elongation through chromatin (Vakoc et al., 2005). The
possibility that H3K9 HMTases might be recruited to the Pol II holoenzyme is supported
by the known association of the H3K4-specific Set1 and H3K36-specific HYPB
HMTases with the elongating Pol II complex (Hampsey and Reinberg, 2003; Sun et al.,
2005).

Figure 5.3 Expanded alignment of potential histone mimics. H3K9-like
motifs are shown in red with potential phosphorylation sites in yellow. Acidic
domains indicated in green. Abbreviations: FACT, facilitates chromatin
transcription; TRF1, Telomeric Repeat-binding Factor 1; RPA194, RNA
Polymerase I 194 kD subunit; NALP6, NACHT/LRR/Pyrin-domain containing
protein 6.
Significantly, many proteins containing potential histone mimics further resemble G9a
in that they contain multiple mimic sites and/or an extremely acidic region (in hG9a, a
stretch of 28 consecutive glutamic or aspartic acid residues). Examples include FACT,
the telomere repeat binding factor TRF1, RNA Pol I β subunit, and the cytosolic pro-
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inflammatory signal transducer NALP6 (Figure 5.3). Highly acidic domains are in
general characteristic of molecules which possess histone chaperone activity (e.g.
nucleoplasmin, CAF-1), the ability to promote histone deposition onto naked DNA
templates (Philpott et al., 2000). FACT in particular is known to behave as a histone
chaperone, and is required both for transcription through chromatinized templates, as
well as for redeposition of histones after Pol II-mediated transcription (Belotserkovskaya
and Reinberg, 2004; Schwabish and Struhl, 2004). The acidic C-terminus of FACT has
been studied in detail, and is critically required for histone chaperone activity
(Belotserkovskaya et al., 2003).
Taken together, these finding suggest a model in which G9a and/or GLP could
become associated with the elongating RNA Pol II complex. This association would
allow co-recruitment of HP1γ to actively transcribed genes via G9a MS2
automethylation, in addition to recruiting other (as yet unidentified) proteins via MS1
methylation. The acidic domain of G9a might then function as a histone chaperone,
similar to FACT, in order to evict histones ahead of the Pol II complex or redeposit
replacement histones behind the complex. Such association between G9/GLP and Pol II
could allow redeposition of modified histones co-transcriptionally, thus perpetuating the
pre-exising pattern of histone modification, as has been observed to occur endogenously
(Kouskouti and Talianidis, 2005).

5.6 Possible extension of histone mimicry to viruses
While the precise functions of histone mimics currently remain elusive, the
cumulative evidence indicates that histone mimicry may represent a fundamental protein
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regulatory mechanism. An interesting test of this hypothesis is whether histone mimicry
as a mechanism is conserved in viruses, which naturally evolve to exploit key cellular
processes. Abundant evidence exists that viruses actively utilize host chromatin
functions to promote their replication. An example of this is the adenoviral E1A protein,
which functions to force quiescent G0 cells into the cell cycle, thus promoting viral
replication. This is accomplished through derepression of target genes normally silenced
by the pRb-related protein p130, and this reactivation is associated with dramatic loss of
H3K9 methylation on target promoters and replacement of this mark with H3K9
acetylation (Ghosh and Harter, 2003). An even clearer example of viral use of host
chromatin factors is the double bromodomain-containing protein Brd4, which is directly
used by the bovine papillomavirus E2 protein to tether the viral genome to mitotic
chromosomes (McBride et al., 2004; You et al., 2004). Finally, it was recently found that
both Flock House Virus (FHV, an animal virus normally infecting insects), as well as
Human Immunodeficiency Virus (HIV) encode proteins which act as suppressors of
cellular RNAi-mediated immunity (Bennasser et al., 2005; Li et al., 2002; Lu et al.,
2005).
To date, only one viral SET-domain containing histone methyltransferase has been
described, that encoded by the double-stranded DNA virus Paramecium bursaria
chlorella virus, PBCV-1 (Manzur et al., 2003). PBCV is a large (180 nm diameter, >330
kb genome) virus which infects zoochlorellae, eukaryotic algae which normally live
symbiotically within hosts such as Paramecium bursaria (Van Etten and Meints, 1999).
Chlorella viruses are unusual in that they encode enzymes similar to eukaryotic DNA
methyltransferases, as well as prokaryote-like restriction-modification systems (Van
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Etten and Meints, 1999), suggesting a complex interplay between virally-encoded
proteins and the host genome.
The PBCV HMTase, referred to as vSET, was found to specifically methylate H3K27
(Manzur et al., 2003). Searches of the viral sequence databases with the H3K9 sequence
demonstrated that a protein from PBCV contains a very similar site (Figure 5.2).
Remarkably, manual inspection revealed that this protein (accession number NP_048536)
contains three different H3K9-type sequences. Moreover, this protein is annotated as
having similarity to the mammalian SWI/SNF chromatin remodeling complex subunit
OSA2. Thus, the genome of PBCV simultaneously encodes both a functional histone
methyltransferase, as well as a protein potentially capable of being multiply modified by
this enzyme. The similarity of this putative methylation target to a known chromatin
remodeler suggests that histone mimicry in this context may allow viral control of host
chromatin remodeling machines, potentially contributing to the competition between viral
and host genomes.

5.7 Conclusion
Studies of histone biology have entered an exciting phase, in which it has become
possible to directly test the contribution of particular histone modifications to cellular and
organismal physiology. Using conditional mutagenesis, we have begun to address the
role of the H3K9-specific histone methyltransferase G9a in lymphocyte development and
function. We find that while G9a is largely dispensable for T cell development, it is
critically important for developing B cells. While the mechanism by which G9a, and
H3K9 dimethylation more generally, contributes to B cell development remains to be
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determined, the grossly normal behavior of G9a-deficient peripheral B cells argues for
possible specificity of the developmental defect.
In the course of studying G9a and GLP, we found that histone methyltransferases are
themselves capable of recapitulating many of the main biochemical features of histones.
Through automethylation on an H3K9-like “histone mimic” site, G9a regulates its
association with the methyllysine binding protein, HP1. The ability of this association to
be further modified by phosphorylation of an adjacent residue speaks to the generality of
the histone code, as well as the complexity of the regulatory mechanisms to which
histone-modifying activities are subject. The finding that many other chromatinassociated proteins have the potential to be similarly modified, and that this mode of
regulation may even extend to viral proteins, should guide the way for further studies to
elucidate the varied functions of protein lysine methylation.
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